Modulation of endothelium function by fatty acids

Rahul Mallick · Asim K. Duttaroy

Received: 17 June 2021 / Accepted: 8 September 2021 / Published online: 16 September 2021
© The Author(s) 2021

Abstract
The endothelium acts as the barrier that prevents circulating lipids such as lipoproteins and fatty acids into the arterial wall; it also regulates normal functioning in the circulatory system by balancing vasodilation and vasoconstriction, modulating the several responses and signals. Plasma lipids can interact with endothelium via different mechanisms and produce different phenotypes. Increased plasma-free fatty acids (FFAs) levels are associated with the pathogenesis of atherosclerosis and cardiovascular diseases (CVD). Because of the multi-dimensional roles of plasma FFAs in mediating endothelial dysfunction, increased FFA level is now considered an essential link in the onset of endothelial dysfunction in CVD. FFA-mediated endothelial dysfunction involves several mechanisms, including dysregulated production of nitric oxide and cytokines, metaflammation, oxidative stress, inflammation, activation of the renin-angiotensin system, and apoptosis. Therefore, modulation of FFA-mediated pathways involved in endothelial dysfunction may prevent the complications associated with CVD risk. This review presents details as to how endothelium is affected by FFAs involving several metabolic pathways.

Keywords Endothelial cells · Atherosclerosis · CVD · FFA · LCPUFAs · Metaflammation · Prostaglandins

Introduction
The tightly regulated vascular endothelium forms a vast interface between the flowing blood and neighboring tissues. The endothelium, which consists of a monolayer of endothelial cells, has a thickness of \( \leq 1 \) μm and covers a total surface area of 4000-7000 m\(^2\). Endothelial cells play various roles in...
the maintenance of vascularity of endothelium. Endothelial cells are responsible for a wide range of critical functions, including maintaining vascular tone, fluidity of blood, blood flow, and permeability of endothelium [1, 2]. In addition, the endothelium regulates normal functioning in the circulatory system by balancing vasodilation and vasoconstriction between thrombosis and hemostasis by modulating the several responses and signals [1, 3]. Thus, impairment of the endothelial functions plays deleterious roles in developing various disorders/diseases, including inflammatory angiitis syndrome, thrombotic embolism, disseminated intravascular coagulation disorder, neovascularization, tumor progression, and diabetic retinopathy [4].

The presence of atherosclerosis is a prevalent characteristic in cardiovascular disease (CVD), and that endothelial dysfunction is thought to be one of the early steps in the pathogenesis of atherosclerosis. Endothelial cells can affect various pathophysiological properties by producing different molecules [5]. Endothelium-secreted compounds such as angiotensin II (Ang II), endothelin-1 (ET-1), thromboxane (Tx) A2, and prostaglandin (PG) H2 involve in vasoconstriction, whereas nitric oxide (NO), prostacyclin (PGI2), bradykinin, and hyperpolarizing factor involve in vasodilation thus maintain a balance between the vasoconstriction and vasodilation [3]. Although dysregulated NO production is the main regulator of endothelium dysfunction, PGI2 and bradykinin also participate in regulating endothelium function. Therefore, the delicate balance between these endothelium-secreted molecules is critically required for the appropriate functioning of the endothelium [5]. Located at the interface between the circulation and the vessel wall, the endothelium reacts by synthesizing and releasing vasoactive substances with anti-thrombotic, vasodilating, and anti-atherogenic properties to maintain vascular homeostasis [6, 7].

The endothelium has a major function in regulating vascular tone, controlling blood flow, and blood fluidity and inflammatory responses [7, 8]. The inner layer of endothelium that comprises endothelial cells allows free blood flow and its cellular components. In addition, endothelial cells produce various factors regulating cellular adhesion, platelet aggregation response, smooth muscle cell proliferation, and inflammation [8, 9]. In addition, the endothelium exerts multiple actions on the expression of several pro-inflammatory genes, including those encoding adhesion molecules, chemokines, and other soluble cytokines of the endothelium [10–12].

Endothelial biology is affected by circulating lipids such as triglycerides-rich particles, chylomicron resident time, lipoproteins, and free fatty acids (FFAs) [13]. FFAs are released into the blood through the action of hormone-sensitive lipase on triacylglycerol stores in adipose tissue. Chylomicrons also contribute to plasma FFA levels, especially when high-fat diets are consumed. Increased plasma FFAs cause insulin resistance and endothelial dysfunction. The most observed lipid abnormalities in type 2 diabetes, metabolic syndrome, and CVD are hypertriglyceridemia, hyperlipoproteinemia, higher levels of FFAs, greater levels of small dense low-density lipoprotein (LDL) [14]. Several human epidemiologic and clinical intervention data suggested the association between circulating triacylglycerol levels and atherosclerosis [15, 16]. Plasma levels of FFAs, a well-established risk factor of CVD [17] are strongly associated with metabolic syndromes, obesity, and type 2 diabetes mellitus [18]. Several studies demonstrated that FFAs modulate the endothelial function and subsequent atherosclerosis processes. Elevated FFAs directly affect transcription factors of several genes involved in inflammation and oxidative stress in the endothelium.

FFA-induced endothelial dysfunction is mediated via several mechanisms, including impaired insulin signaling, dysregulation of NO synthesis, oxidative stress, inflammation, and the activation of the renin-angiotensin system (RAS) and apoptosis. Insulin resistance, oxidative stress, and inflammatory conditions are responsible for FFA-induced endothelium dysfunction [19–21]. Activation of endothelial cells by inflammation, proliferation, hypercoagulability, activation of vasoactive factors, enhanced apoptosis, increased vascular permeability, presence of free radicals is defined as endothelial dysfunction [22]. Because of the multifaceted roles of plasma FFAs in modulating endothelial function, elevated FFA level is now considered an essential link in the onset of endothelial dysfunction due to metabolic syndromes such as diabetes and obesity. Therefore, modulation of the signaling pathways involved in FFA-induced endothelial dysfunction may protect against endothelial dysfunction and subsequent CVD complications such as atherosclerosis.

Endothelial dysfunction is a significant feature in atherosclerosis, hypertension, diabetes, and cardiovascular disorders [7, 23]. Defective endothelium results in leukocyte adhesion, activation of platelets, pro-oxidation of mitogens, dysregulated synthesis of PGI2, NO, and endothelium-derived hyperpolarizing factor (EDHF), and other vasoconstriction factors such as Ang II and PGH2, resulting in atherosclerosis and thrombosis [24]. A balance between the levels of vasoconstrictors (TxA2, PGH2, ET-1) and vasodilators (NO, EDHF, PGI2) produced by the endothelium determines the vascular tone. The expression of adhesion molecules on endothelial cells also plays an important role in the atherosclerosis process. The adhesive molecules expressed on endothelial cells are selectins, intracellular adhesive molecules (ICAMs), and vascular adhesive molecules (VCAM-1).

This review aimed to describe the roles and fundamental mechanisms of FFA-mediated endothelial dysfunction. Moreover, how the endothelium participates in the uptake
and metabolism of fatty acids and involves various biochemical pathways in health and disease is also discussed.

**Effects of fatty acids on endothelial function**

Fatty acids are taken up and metabolized by endothelial cells, depending on the chain length, number, and position of double bonds. Fatty acids are beta-oxidized into mitochondria to fuel the tricarboxylic acid cycle and produce ATPs. At the same time, excess intracellular fatty acids are stored as cytosolic lipid droplets [25]. Protection from endoplasmic reticulum stress from excess FFA is correlated with endothelial stored lipid droplets [25]. Fatty acids are also synthesized de novo by endothelial cells even though they can uptake FFAs [26, 27]. Fatty acids are transported to mitochondria by the rate-limiting enzyme carnitine palmitoyltransferase 1a, the key to fatty acid oxidation and endothelial permeability [28, 29].

High levels of blood FFAs affect endothelium function in different ways. First, FFAs may contribute to inflammation resulting in increased permeability of the endothelium. Second, elevated blood levels of FFAs also down-regulate insulin-mediated production of NO and reduce blood flow peripherally. FFAs mediate these effects via two different mechanisms by (a) decreasing tyrosine phosphorylation IRS-1/2 and preventing the PI3K/Akt pathway, which regulates insulin-stimulated glucose uptake and NO production by endothelial nitric oxide synthase (eNOS) [18]. Figure 1 describes the mechanism of FFA-induced endothelial dysfunction.

In contrast, the endothelium-independent vasodilation remains unaffected [30], indicating that FFAs have specific inhibitory effects on NO synthesis by the endothelial cells. Infusion of FFA in insulin-sensitive human subjects was shown to significantly reduce NOS flux and impair shear stress-induced NO synthesis [31]. Palmitoylation of eNOS regulates the bioavailability of endothelial eNOS and thus NO release [32]. During atherosclerotic plaque formation, endothelial barrier, aberrant NO production, ROS production, and pro-inflammatory and pro-coagulative factors cause endothelial dysfunction, which enhances LDL transcytosis, upregulation of LDL oxidation, activation of blood platelet and leukocytes [33]. N-6 polyunsaturated fatty acids (PUFAs) may lower LDL cholesterol but increase LDL cholesterol susceptibility to oxidation and lower HDL cholesterol. Monounsaturated fatty acids are more beneficial than SFA and n-6 PUFAs in terms of their effects on LDL oxidizability [34]. They also prevented n-3 fatty acids from exerting their potential adverse effects of LDL oxidation. 15-Lipoxygenase is implicated in the in vivo oxidation of LDL and is a process thought to involved...
in initiation and progression of endothelium dysfunction and atherosclerosis.

More specifically, inhibition of eNOS mRNA expression by FFAs was shown in rat aortic endothelial cells, thus lowering the eNOS activity and increased oxidative stress and inflammatory status [35]. FFAs downregulate insulin-mediated eNOS activity through upregulation of PTEN (phosphatase and tensin homolog) and simultaneous inhibition of Akt kinase [36]. The AMPK/Pi3K/Akt/eNOS pathway in endothelium dysfunction was diminished with elevated levels of FFAs due to consuming a high-fat diet [37].

FFAs increase ROS levels in monocytes dose-dependently, leading to adhesion of the monocytes to the endothelial cells [38]—a critical mechanism in the development of atherosclerosis [39]. Furthermore, FFAs-induced increases in CVD risk factors, characterized by elevated endothelial markers, are also observed in healthy subjects [40]. Therefore, clinical and experimental studies exploit the protective effects of several dietary fatty acids/functional foods and drugs via suppression of inflammatory conditions and oxidative stress in FFA-induced endothelium dysfunction. As observed in human studies, calcium channel blockers such as dihydropyridine and amlodipine prevent FFAs-induced endothelium dysfunction, leucocyte activation, and oxidative stress. The protective effects of these drugs are mediated by the suppression of NF-κB p65 phosphorylation [41]. Moreover, these compounds involve in the nuclear localization of Nrf2 and reduce oxidative stress and enhance the expression of the cytoprotective genes in endothelial cells.

The RAS is one of the critical determinants of arterial blood pressure, and Ang II is a potent vasoconstrictor. The endothelial cell membrane expresses the angiotensin-converting enzyme (ACE) that produces Ang II. Ang II induces vasoconstriction by stimulation of endothelium and exhaustion of NO. Therefore, inhibition of ACE stimulates vasodilation via the NO pathway [42]. While Ang II increases FFAs levels via downregulating the fatty acid oxidation [43], on the other hand, FFAs also activate the RAS system [44]. ACE-/- mice had increased expression of genes responsible for lipolysis and oxidation of fatty acids [45], explaining the possible interplay between RAS and FFAs. By activating leukocytes, thus FFAs contribute to the adhesion of leukocytes to the endothelium in an Ang II-dependent manner, leading to the initiation of endothelium dysfunction [46]. Consequently, inhibition of the RAS prevents the FFA-induced endothelium dysfunction [47]. A single dose of either losartan (an Ang II receptor antagonist) or perindopril (an ACE inhibitor) completely prevented the FFAs-induced dysregulation of endothelium-dependent vasodilation, suggesting the blockade of RAS as an effective treatment for FFAs-induced endothelium dysfunction [47].

The risk of CVD is associated with saturated fatty acids (SFAs). In contrast, unsaturated fatty acids are unlikely involved in CVDs, and instead, these fatty acids are mostly found beneficial in CVD. SFAs increase blood LDL levels, a significant risk factor for CVDs [48]. Studies have demonstrated that long-chain saturated fatty acids (c > 14) (LCFAs) impart a greater risk for CVD than by the medium-chain fatty acids (8-12) (MCFAs) [48]. The most common saturated LCFAs present in the western diet are myristic acid, 14:0 (MA), palmitic acid, 16:0 (PA), and stearic acid, 18:0 (SA). While SFAs have been shown to increase total cholesterol and LDL cholesterol, there is also an increase in high-density lipoprotein (HDL) cholesterol [49]. CVD risk associated with SFAs varies from no association to a significantly significant risk [50]. SFAs, depending on chain length, have diverse effects on cholesterol metabolism in the body. For example, stearic acid, 18:0 (SA), is considered neutral on cholesterol metabolism compared with the other long-chain SFAs due to its high conversion rate to oleic acid 18:1n-9 (OA) by Δ9-desaturase enzyme. Long-chain SFAs, the health impact of stearic acid has no harmful effect on CVD risk. SFAs exert their atherogenic and thrombogenic influence through increased production of VLDL particles and ApoA1, decreasing LDL receptor-specific activity and increased platelet aggregation [51]. Unlike other SFAs, SA showed no atherogenic or thrombogenic effect since, after absorption, it is desaturated to monounsaturated fatty acid, OA, which is associated with a beneficial effect on cardiovascular health. OA is incorporated into phospholipids rather than into triglycerides and cholesterol esters. OA exerts significant beneficial effects on atherosclerosis and thrombosis [52–54].

Various studies have concluded that PA substantially contributes to the development of atherosclerosis [55]. Both in vivo and in vitro studies have demonstrated the mechanisms by which PA contributes to the pathogenesis of CVDs. PA promotes inflammatory responses and cellular senescence in cardiac fibroblasts. PA achieves senescence in these cells by activating toll-like receptor 4 (TLR4) and NLRP3 inflammasome, increasing mitochondrial ROS levels [56]. PA also induces apoptosis of the vascular smooth muscle cells by inducing the TLR4 pathway and generating ROS [57]. Both PA and SA downregulated eNOS in porcine aortic endothelial cells. Although PUFA's have a protective role against endothelium dysfunction [58], their elevated FFAs adversely affect the endothelium by decreasing NO release and increasing ET-1 levels. Linoleic acid, 18:2n-6 (LA) negatively regulates eNOS phosphorylation and affects the intracellular NO levels in ECV304 cells [59].

Many clinical studies showed protective effects of OA on flow-mediated dilation and other endothelial markers; however, they did not focus on FFA-induced endothelium dysfunction [60–62]. Studies demonstrated that n-3 long-chain polyunsaturated fatty acids (LCPUFAs) such as docosahexaenoic acid, 22:6n-3 (DHA), eicosapentaenoic acid, 20:5n-3
(EPA), and polyphenols were beneficial in FFA-induced endothelium dysfunction [59, 63–65]. The mitochondria-related AMPK/eNOS pathway alleviates endothelium dysfunction and atherosclerosis in mice fed with a high-fat diet [66]. L-carnitine, an essential factor for fatty acid transport/oxidation in the mitochondria, attenuates FFA-induced obesity-related endothelium dysfunction in human subjects [67].

Moreover, SA showed a similar reducing impact on platelet aggregation and coagulation factors as the OA and LA [68]. Besides, a high-fat diet, a significant source of SFAs in blood levels of FFAs, induces oxidative stress in endothelium [69]. Elevated FFAs induce expression of NADPH and mediates oxidative stress in rats with characteristics of both obesity and type 2 diabetes mellitus [70]. FFAs-induced endoplasmic reticulum stress was observed in endothelial cells isolated from healthy human subjects [71]. Infusion of intralipid in healthy subjects increased FFAs by a 4.2-fold increase, and that was associated with reducing the hyperemic response in the leg without a change in flow-mediated dilation of the brachial artery. The mRNA levels of the genes ATF6 and IRE1, responsible for early adaptive responses to endothelium reticulum stress, increased in endothelial cells.

Trans fatty acids (TFAs), obtained from partial hydrogenation of plant oils, have the highest atherogenic activity. Thus industrial foods—cakes, cookies, and crackers often contain a high content of TFAs. TFAs have one double bond in which the hydrogens are on the opposite side to one another resulting in physiochemical properties close to those of SFAs. Main TFAs are elaidic acid, 18:1n-9t, and trans-vaccenic acid, 18:1n-7t. TFAs are associated with a higher risk of CVD and type 2 diabetes mellitus [72]. Consumption of TFAs increased plasma LDL cholesterol, lowered HDL cholesterol, and increased lipoprotein (a) and plasma triglyceride levels [73] and smaller flow-mediated vasodilation [74]. TFAs can influence the thrombotic state through the eicosanoid synthesis pathway [72]. TFAs also adversely affect endothelial function, which partly explains their association with CVD risk [75]. Intake TFAs also induced inflammation and endothelial dysfunction, as evidenced by increased plasma levels of CRP, IL-6, soluble tumor necrosis factor receptor (TNF-2), E-selectin, and soluble intercellular and vascular cell adhesion molecules (sICAM-1 and sVCAM-1) in apparently healthy women [75]. TFAs also activate the NF-κB pathway that increases endothelial superoxide production and reduces NO synthesis [76]. FFAs-induced endothelium dysfunction is mediated via the activation of NF-κB [77]. Thus, the NF-κB pathway is a significant player mediating the harmful effects of TFAs on human coronary artery endothelial cells [78].

FFAs-induced NLRP3 inflammasome also increases endothelial permeability. PA activates the NLRP3 inflammasome with a resulting decrease in endothelial tight junction proteins—zonula occludens-1 and -2 in microvascular endothelial cells. FFAs also increases the synthesis of high-mobility group box 1 (HMGB1) protein, which might explain the early onset of endothelial injury during obesity by FFAs.

Endothelial progenitor cells (EPCs) participate in endothelial recovery following arterial injury and oxidative stress-induced damages [79]. Dysfunctional EPCs are involved in the pathogenesis of CVD [80]. PA contributes to the apoptosis of EPCs mediated via the p38 and JNK/MAPKs pathways [81]. PA has harmful impacts on EPCs in metabolic syndrome patients via regulating long non-coding RNA (LncRNA) maternally expressed gene 3 (MEG3) [81]. These data raise interest for further studies on the pathophysiological roles of MEG3 in both EPCs and endothelial cells.

**Metabolism of n-3 and n-6 long-chain polyunsaturated fatty acids and their impacts on endothelium**

Dietary polyunsaturated fatty acids (PUFAs) commonly consumed by humans encompass two major groups: the n-3 and n-6 families of fatty acids. Linoleic acid, 18:2n-6 (LA) and alpha-linolenic acid, 18:3n-3 (ALA) are the dietary essential fatty acids (EFAs) [82]. LA and ALA are not interchangeable but can be further elongated and desaturated by the same enzyme systems to produce n-6 and n-3 LCPUFAs in the body. Some common n-3 PUFAs include ALA, EPA and DHA, and common n-6 ones include LA and arachidonic acid, 20:4n-6 (ARA). LCPUFAs are the precursors for eicosanoid biosynthesis and various signaling compounds with relevant roles in human health and disease. Whereas dietary LA and ALA are primarily from vegetable oils, preformed LCPUFAs may also be consumed in animal-origin foods. The importance of LCPUFAs has been related to their structural action, their specific interaction with membrane proteins, and their ability to serve as precursors of second messengers. LCPUFAs (20 carbon) are substrates for cyclooxygenase (prostaglandin-endoperoxide synthase) and lipoxygenases and produce various compounds collectively called eicosanoids. These compounds have diverse biological functions in cell growth and development, inflammation, and the cardiovascular system. The biological response elicited after eicosanoid release is dependent on the net balance of eicosanoids derived from n-6 and n-3 LCPUFAs. ARA is the most predominant precursor fatty acid of the highly biologically active eicosanoids of the 2 series in the Western diet. Also, the endogenous formation of cyclooxygenase and non-cyclooxygenase metabolites of fatty acids has been implicated in gene expression. Because each type of EFA can interfere with the other’s metabolism, an excess of n-6 fatty acids will reduce the metabolism of ALA, possibly leading to a deficit of n-3 LCPUFA metabolites. Therefore,
a proper balance between the n-6 and n-3 fatty acids in the diet is essential to maintain optimum health.

Endothelial cells metabolize ARA in three different ways, cyclooxygenase (COX), lipoxygenase, and cytochrome P450 system. The primary metabolites of the COX pathway are PGI2 with lesser amounts of PGE2, TxA2, and 12-hydroxyeicosatetraenoic acid [83], 12- and 15-hydroxyeicosatetraenoic acids are the primary lipoxygenase metabolites. Endothelial cells synthesize the four regioisomeric epoxyeicosatrienoic acids (EETs), 14,15,- 11,12-, 8,9-, and 5,6-EETs, with 14,15- and 11,12-EETs the significant metabolites. EETs are cytochrome P450 epoxygenase metabolites of ARA. PGE2 and TxA2 play an essential role in maintaining vascular homeostasis [83]. PGI2 is a vasodilator and a platelet aggregation inhibitor, whereas TxA2 is a vasoconstrictor and an activator/aggregator of blood platelets [84, 85]. PGI2 has vasodilating properties, inhibits platelet aggregation by elevating intracellular levels of cAMP [86]. At the same time, vasorelaxation and platelet inhibitory actions of NO are mediated predominately by activating intracellular guanylyl cyclase, leading to cGMP formation [8]. Thus, PGI2 and TxA2 play a critical role in maintaining vascular homeostasis. PGI2 is a vasodilator and an inhibitor of platelet aggregation, whereas TxA2 is a vasoconstrictor and a promoter of platelet aggregation [86, 87]. Therefore, an imbalance in PGI2 or TxA2 production is implicated in the pathophysiology of many thrombotic and cardiovascular disorders [83, 87]. The protective effect of PGI2 against the development of CVD is mediated through the inhibition of various cellular processes, including inhibition of platelet activation, leukocyte adhesion to endothelium. Prostaglandins also enhance endothelial cell survival through the upregulation of the anti-apoptotic protein B cell lymphoma (Bcl)-2 [88] and the activation of phosphatidylinositol (PI)3-kinase (K)-Akt pathway [89].

N-6 LCPUFAs mediate acute inflammatory responses by synthesizing pro-inflammatory eicosanoids [90], whereas n-3 LCPUFAs produce anti-inflammatory or neutral eicosanoids. ARA-derived eicosanoids control cellular membrane lipid composition, inflammation, coagulation, and vascular homeostasis [91, 92]. Also, ARA-induced synthesized cytokines and adipokines play a vital role in metabolism and inflammation [93]. LA induces inflammation by increasing the levels of TNF-α, MCP-1, VCAM-1, and ICAM-1 through the activation of NF-κB and activator protein 1 (AP-1) [94], and it affects the release of NO [95].

Circulating blood platelets do not attach to the negatively charged surface of the endothelium. However, the activated platelets can bind GP Ib/IX to either P-selectin or VWF on the surface of the endothelium, and indirectly via a fibrin bridge that joins GP Ib/IXa and ICAM-1. Whereas NO decreases the intracellular level of Ca2+, the transformation of GPIIb/IIIa platelet receptor and suppresses the integrin’s binding to fibrinogen [96, 97]. The ecto-ADPase (CD-39), on the surface of endothelial cells, hydrolyzes both ATP and ADP to generate AMP, thus decreases platelet aggregation/activation [86, 96]. TxA2 produced by the endothelium from ARA, aggregates platelets and expresses adhesive co-factors for platelets such as vWF, fibronectin, and thrombospondin procoagulant factors such as factor V [84, 98].

Endothelial cells actively prevent thrombus formation by suppressing platelet adhesion and activation [99]. The vasoprotective function of endothelial cells is also associated, among others, with biosynthesis and release of NO, PGI2, PGE2, and tissue plasminogen activator (tPA). Platelet activation is counteracted by PGI2 and PGE2, produced from ARA by the endothelium after activation by various vasoactive agents, including thrombin. PGI2 is produced by the endothelium of large vessels, while the endothelial cells from smaller vessels produce PGE2 [100]. The effect of PGI2 is enhanced by NO produced by endothelial nitric oxide synthase (eNOS). The endogenous fibrinolytic system is responsible for the dissolution of the thrombus. It is regulated by the endothelium-derived pro-fibrinolytic factor, tissue plasminogen activator (tPA), and its inhibitor, plasminogen activator inhibitor type-1 (PAI-1) [101]. Fatty acids, depending on their structure, regulate PAI-1 and tPA activity. However, the definitive conclusions are yet to be reached [102–104]. These endothelium-derived compounds can inhibit activation of platelets and leukocytes, promote fibrinolysis, maintain tissue perfusion and protect the vascular wall against acute damage and chronic remodeling. Endothelial dysfunction is associated not only with suppression in the release of these compounds but also with the secretion of deleterious compounds such as PGH2, PGG2, superoxide anion (O2-), peroxynitrite (ONOO-), and plasminogen activator inhibitor (PAI-1).

Several epidemiological, experimental, and clinical studies indicate that n-3 fatty acids can decrease CVD risk via several mechanisms, including improving vascular function. Incorporation in cell membranes, n-3 PUFAs precisely activate cardiovascular protective signaling pathways [105], increase NO production [106], reduce oxidative stress [107] and inflammation [12]. N-3 fatty acids also increase eNOS expression in the endothelium via several pathways such as phosphorylation of AMPK [63] and increased expression of eNOS mRNA [108]; stimulation of SIRT-1 and heat-shock protein 90 protein [109, 110]; and finally, eNOS translocation from caveolea to the cytosol [111]. N-3 PUFAs can decrease the expression of these adhesive factors of endothelial cells and thus reduce the activation of the endothelium.

The vasoprotective properties of n-3 fatty acids include decreased arterial plaque formation, anti-inflammatory activity, improved endothelial-dependent vasodilation, lowered arterial blood pressure, and increased antioxidant activity. N-3 fatty acids reduce arterial stiffness and blood pressure.
via eNOS expression. Monocyte–endothelium interaction is essential in many acute and chronic inflammatory diseases. Both EPA and DHA significantly reduce PAF synthesis, monocyte rolling, and adherence, whereas endothelial adhesion molecules expression was unaltered.

Both EPA and DHA compete with ARA as substrates to form pro-inflammatory mediators, such as 4 series of leukotrienes, 2 series of prostaglandins, and cytokines. In addition to competitive inhibition of the n-6 fatty acid pathway, n-3 fatty acids also inhibit the production of C reactive protein, TNFα, matrix metalloproteinase (MMP)-2 and MMP-9, and tissue inhibitors of MMP [114–116]. Furthermore, N-3 fatty acids inhibit COX-2 expression as therapeutic potential as COX-2 overexpression is involved in different inflammatory/degenerative diseases apart from atherosclerosis [112].

Endothelial cells express ICAM-1, VCAM-1, E-selectin, and P-selectin involved in leukocyte recruitment and platelet adhesion during thrombosis and inflammation and contribute to early phases of atherosclerosis. Cytokine-induced endothelial activation involves increased expression of genes for ICAM-1, VCAM-1, and E-selectin, whereas n-3 PUFAs suppress the synthesis of inflammatory cytokines that activate the endothelium. Thus, n-3 PUFAs decrease atherosclerosis and inflammation by reducing the expression of adhesion and migration of monocytes to the endothelium.

N-3 LCPUFAs supplementation replaces ARA content in plasma membrane phospholipids to improve endothelium vasodilating effects [117]. Thus, n-3 PUFAs can modify n-6 eicosanoids production to favor vasodilation and anti-thrombotic actions. N-3 PUFAs increase endothelial-dependent relaxation by increased release of NO. NO inhibits platelet aggregation and adhesion, leukocyte adhesion, and smooth muscle cell proliferation. The protective role of n-3 LCPUFAs has been shown by reducing FFA-induced endothelium dysfunction via the AMPK/PI3K/Akt/eNOS pathway. EPA has a protective role against PA-induced endothelium dysfunction mediated via activation of the AMPK/eNOS pathway. EPA also inhibited PA-induced apoptosis of endothelial cells and activated apoptosis-related proteins, such as caspase-3, p53, and Bax [63]. N-3 PUFAs can protect endothelium by reducing platelet TxA2 synthesis, plasminogen activator inhibitor–1 activity, COX 1 or 2 productions, platelet activation, and adhesion to endothelium [118–121]. Moreover, n-3 PUFAs interfere with the vitamin K-dependent carboxylation of coagulation factors II, VII, IX, and X) [122, 123].

Dietary n-3 PUFAs reduce plasma triglycerides and very-low-density lipoproteins (VLDL) [124–126] and thus protect the endothelium from lipid stress. Inhibition of 1,2 diglyceride acyltransferase or sterol regulatory element-binding protein 1c by n-3 PUFA reduces hepatic triglyceride synthesis [127–129]. Also, n-3 PUFA activates peroxisome proliferator-activated receptor alpha (PPARα) to favor catabolism of circulating triglycerides and VLDL by promoting fatty acid beta-oxidation [127, 130]. N-3 PUFA induced non-proteinase degradation of apolipoprotein B reduces naïve hepatic VLDL secretion [131–133]. Several studies found that n-3 PUFAs increase HDL levels despite fluctuating effects on LDL levels, possibly by decreasing cholesteryl ester transfer protein activity [134–138].

As an independent risk factor of CVDs, hypertension can be favorably regulated by n-3 PUFAs supplementation [139, 140]. N-3 PUFAs mediated blood pressure regulation by producing vasodilator prostaglandins, activating eNOS, increasing renin release from the kidney, suppressing ACE activity, and activating large-conductance Ca2+-activated K+ channels has been demonstrated [141–144]. In addition, studies found that reduced n-3 PUFAs on red blood cells induce vasoconstriction and increased production of pro-inflammatory eicosanoids [145, 146].

**Fatty acid transport across the endothelium**

Fatty acids pass through the endothelial cell membrane to enable tissue uptake in muscle and likely allow fatty acids to penetrate the arterial wall. The trans-endothelial crossing could take place through movement around or between endothelial cells. Large topical concentrations of FFAs disrupt the endothelial barrier, as does active lipolysis, which can also upregulate LDL passage into the artery [147]. Fatty acid uptake by endothelial cells is not entirely understood clearly; it might involve both protein-mediated uptake and non-specific uptake [148], which might occur in the presence of high topical fatty acid concentrations, e.g., those that occur during chylomicron but not VLDL lipolysis [149]. Fatty acid metabolism by vascular endothelial cells occurs both under basal conditions and following endothelial cell stimulation or injury.

Endothelial cell reigns in the metabolic homeostasis of the various tissues via their growth and function. Endothelial cell activates in response to vessel wall permeability and interaction with multiple molecules of blood. However, glucose is the primary source of endothelial energy, fatty acid uptake, transport, and metabolic pathways on endothelial cells have become an arena of interest for many years [150]. As the metabolic gatekeeper, endothelial cells regulate fatty acid transcytosis, and dysregulated endothelial fatty acid transport can pronounce insulin resistance, which plays a pivotal role in various pathological processes [151].

Endothelial fatty acid transport can be either passively by crossing paracellularly through intercellular space between neighboring endothelial cells or actively, where fatty acids cross the endothelial layer by different transporters such as plasma membrane fatty acid-binding protein (FABPpm), fatty acid transport proteins (FATPs),
cluster of differentiation 36 (CD36), or fatty acid translocase (FAT), and cytoplasmic fatty acid-binding proteins (FABPs) [152]. Unlike fenestrated hepatic endothelial lining, continuous and non-fenestrated cardiac endothelial lining signifies the importance of the endothelial fatty acid transport system. Unlike medium and short-chained fatty acids, generally consumed long dietary chain (c ≥ 14 carbons) fatty acid uptake in endothelial cells is upregulated by synergistic co-expression of FATP3 and FATP4. Secretion of vascular endothelial growth factor B by cardiomyocytes or production of 3-hydroxy-isobutyrate by skeletal muscle regulates the expression of FATP3 and FATP4 in neighboring endothelial cells [27, 153]. FATP4 and FATP5 are mainly expressed by capillaries and venules of the heart, skeletal muscle, and adipose tissue [154]. Apelin signaling within endothelial cells inhibits FATP4 expression by activating transcription factor FOXO1, which may stabilize VE-cadherin-mediated endothelial cell junctions [155, 156]. In cardiac and skeletal muscle, deficiency of fatty acid uptake is compensated by glucose uptake for energy production [154]. Figure 2 describes the prostanoid-induced angiogenic role of COX-2 in endothelial cells.

FAT/CD36 facilitates fatty acid transport across the endothelial layer and oxidation in the heart, skeletal muscle, and adipose tissue [157, 158]. Silencing FAT/CD36 or lipoprotein lipase downregulates peroxisome proliferator-activated receptor alpha mediated cardiomyocyte lipid deposition, ultimately resulting in lipotoxic cardiomyopathy [159]. Surprisingly the opposite effect of FAT/CD36 is observed in the liver, which may be due to the high permeability of hepatic endothelial cells comparatively [160]. As the principal regulator of fat metabolism, peroxisome proliferator-activated receptor-gamma (PPARγ) maintains different fatty acid transport proteins expression, including FAT/CD36 in nonfenestrated endothelium [161]. Ultimately fatty acid transport, storage, and release in heart, skeletal muscle, and adipose tissues solely depend on PPARγ [162].

Surprisingly, when fatty acid level crosses the metabolic limit, FAT/CD36 becomes dysfunctional and consistently stays at the plasmalemma [163]. Although n-3 PUFAs downregulate the ongoing relocation of FAT/CD36 on

---

**Fig. 2** Rate limiting the prostanoid-induced inflammatory angiogenic role of COX-2 on endothelial cell. N-3 or N-6 LCPUFA6 (DHA, EPA and ARA) from dietary or metabolism are incorporated into cell membrane phospholipids. DHA, EPA, or ARA can be liberated by phospholipase A₂ or phospholipase C. COX-2 then converts ARA to prostaglandin H₂, which can be inhibited by the liberated DHA, EPA, or COX₂ inhibitors. Prostaglandin H₂ converts into prostaglandin D₂, prostaglandin E₂, prostaglandin F₂α, prostaglandin I₂, and thromboxane A₂ by prostanoid synthase to promote-specific angiogenic steps and mediators.

© Springer
Ca²⁺-dependent phospholipase A₂ activation [174]. Either lized by fenestrated endothelium, but LDL receptors and lipoproteins transport occur on the apical endothelial sur -
genesis and fatty acid transport. Investigate more precisely the relationship between angio-
to insulin resistance [179]. All these findings demand to
FATP₃ expression through integrin α5β1 signaling and key
angiopoietin 2 (ANGPT₂), in modulating FAT/CD₃₆ and has shown the pivotal role of another angiogenic regulator,
sensitivity and glucose tolerance [178]. Even current finding
matically, endothelial Notch signaling interrupts insulin sen-
that plays crucial roles in endothelial cell activation, includ-
1 [188, 189]. FABP₄ also determines the inflammatory func-
ion of endothelial cells by regulating the gene expression
pro-angiogenic activity. In turn, FABP₄ expression is controlled by vascular endothelial growth factor-A (VEGF-
A) and mammalian endothelial target of rapamycin complex 1 [188, 189]. FABP₄ also determines the inflammatory function of endothelial cells by regulating the gene expression that plays crucial roles in endothelial cell activation, including endothelial eNOS and intercellular adhesion molecule 1.
FABP₅ has a 55% amino acid sequence homology with FABP₄ and primarily microvascular expression pattern in endothelial cells [154, 191]. Although, the FABP₅ function in endothelial cells remains unclear. The current research has found the vital role of FABP₄ and FABP₅ in fatty acid uptake in the heart and skeletal muscle endothelial cells [154]. In animal models, combined deficiency of FABP₄ and FABP₅ ensures more excellent defence against insulin resistance, obesity, and atherosclerosis than mice deficient for either FABP₄ or FABP₅ [192, 193]. Along with LCFAₗ₉, FABP₅ binds with PPARα and retinoic acid; upon binding these ligands, it mobilizes to the nucleus to induce PPARα and regulates cell growth and development. Regulation of endothelial cells homeostasis and vascular integrity is vital to organ physiology and tissue repair, regeneration, and tumor growth. Based on the additive functions of FABP₄ and FABP₅ in other cell types and their co-expression in microvascular endothelial cells, FABP₅ played a role in regulating angiogenesis-related endothelial cell functions,
including proliferation, migration, and survival. As a downstream inducer of FABP5-related effects in endothelial cells, the critical role of PPARδ was demonstrated.

The expression of FABP3 and FABP5 has been demonstrated in the microvascular of cardiac tissues and skeletal muscles. Also, FABP4 and FABP5 expressions were figured out in the microvessels of other organs with higher fatty acids metabolic activity, such as hepatic and adipose tissues [194, 195]. Endothelial cells can regulate the expression of FABP5 depending on tissue types and microvasculature [191]. Further investigations are needed to figure out the exact role of FABPs in lipid metabolism.

**Roles of fatty acid metabolism in endothelial cells on angiogenesis**

The metabolism of endothelial cells has only recently been recognized as a driving force of angiogenesis. Metabolic pathways, such as glycolysis, fatty acid oxidation, and glutamine metabolism, have distinct, essential roles during vessel formation. Moreover, endothelial cell metabolism is markedly perturbed in pathologies such as cancer and diabetes. For instance, because tumor endothelial cells increase glycolysis, lowering hyper glycolysis in tumor endothelial cells induces therapeutic benefits in preclinical tumor models. Expanding our knowledge of how endothelial cells alter their metabolism in disease could pave the way for novel therapeutic opportunities. The most recent data describe the association of endothelial cell metabolism in health and disease, emphasizing the changes in metabolism in the tumor endothelium.

The endothelial lining on the vessel wall is crucial for nutrients and oxygen supply to the tissue. Reduced nutrients availability or oxygen tension stimulates activation of quiescent endothelial cells for angiogenesis (de novo blood vessel formation from pre-existing blood vessels) [196, 197]. Angiogenic sprouting involves interaction between endothelial cells and their metabolic microenvironment. First, proangiogenic proteins are secreted from the oxygen and nutrition demanding tissues to activate endothelial cells. Activated endothelial cells extend filopodia (known as tip cells) towards angiogenic stimuli [198]. Migratory tip cells are followed by proliferating endothelial cells (known as stalk cells) to elongate the sprouting process [199]. Endothelial cells continuously compete to take the lead as tip cells [200]. Ultimately tip cells communicate with tip cells of adjacent sprouts to form de novo vascular circuits throughout the process until meeting oxygen and nutritional demands. Then proangiogenic factors downregulate, basement matrix establishes, pericytes recruit to onset perfusion, and endothelial cells become quiescent again. These endothelial cells of de novo blood vessels are defined as phalanx cells [201].

Angiogenesis requires coordinated not only endothelial morphogenic behavior but also metabolic activities. The metabolic activities of endothelial cells are different from other differentiating cells. Rapid energy production is needed for tip cell migration and navigation, while proliferative stalk cells need to produce cellular components [202]. Like cancer cells, around 85% energy production of endothelial cells depends on the aerobic glycolytic pathway [203–205]. Accelerated glycolysis by VEGFA increases endothelial glucose uptake and upregulation of glycolysis activators. Moreover, VEGF induces endothelial cell proliferation through the upregulation of FABP4 [190]. Figure 3 describes the regulation of endothelial metabolism by different factors. Also, VEGFR2 and NOTCH1 activities rely on glycolysis [206, 207]. But hypoxia-induced HIF1α can also activate glycolytic genes, e.g., SLC2A1, LDHA, PFKFB3 [208–210]. PFKFB3 driven glycolysis is vital for tip cell migration and stalk cell proliferation [205]. Although, the rate of glycolysis varies on endothelial subtypes. Microvascular endothelial cells are known to be more glycolytic and proliferative [205, 211]. Despite generating very little ATP, endothelial cells are relied on less efficient glycolysis due to higher endothelial cell glucose uptake capability and faster ATP production [212, 213]. Endothelial cells use stored glycogen for energy production in vascular tissues [214, 215].

Although endothelial cells are not dependent on mitochondria for energy production, mitochondria act as a biosynthetic hub endothelial growth and proliferation. Fatty acid oxidation sustains vessel growth. Stalk cells rely on fatty acid oxidation for their normal functions. Beta oxidation of fatty acids supports the DNA replication process. Shuttled long-chain fatty acids into mitochondria are metabolized to acetyl-CoA, used for the citric acid cycle. The use of fatty acid-derived carbon for nucleotide biosynthesis differentiates endothelial cells from glucose and glutamine-dependent proliferating cells [28, 216]. Maybe during a nutrition-deprived state, endothelial cells catabolize fatty acids from stored lipids. Growth and division, the development of new membrane, the generation of signaling molecules, and modulating cellular signaling, endothelial cells are solely dependent on fatty acids and other lipids [217]. To improve the intracellular lipid storage, oxaloacetate and acetyl-CoA genesis occur into the cytosol from the citric acid cycle derived citrate. Fatty acid synthase enzyme converts acetyl-CoA to fatty acids, which is crucial for angiogenesis and vascular homeostasis [26, 218].

Though, mitochondrial fatty acid biosynthesis diminishes mitochondrial integrity due to exhaust the citric acid cycle intermediates. Anaplerosis (the replenishing process of the citric acid cycle intermediates) can only prevent mitochondrial disintegration and cell death [212]. As an essential nitrogen source for nucleotide biosynthesis, endocytosed non-essential amino acid glutamine converts to glutamate...
Glutaminase is the rate-limiting enzyme for the conversion of glutamine. Upregulation of glutaminase activity is apparent during angiogenesis [220]. Besides anaplerosis, glutamine can be used for energy production, biosynthesis of glutathione, and reductive carboxylation for lipid production [219, 221]. Prostanoids mediate angiogenesis through multiple mechanisms, including the induction of VEGF production [222], the stimulation of endothelial cell sprouting, migration, and tube formation [223–225].

Although extracellular-regulated kinase phosphorylated, MYC (V-Myc avian myelocytomatosis viral oncogene homolog) regulates endothelial metabolism and growth factor signaling for cell growth, proliferation, and anabolic metabolism [226, 227]. In addition, accumulated MYC increases glycolysis, mitochondrial function, and cell cycle progression [228]. Many studies focused on angiogenic endothelial cells; however, the metabolic role of quiescent endothelial cells is critical for normal vascular function.

Transcription factor FOXO1 drives endothelial quiescence by reducing overall metabolic activity. In addition, FOXO1 suppresses MYC activity [226].

Interestingly, quiescent endothelial cells consistently reduce glucose uptake or glycolysis and increase fatty acid uptake [29]. The change in nutrient utilization or slower metabolic rate in quiescent endothelial cells needs to be elucidated. Reduced metabolic activity helps stabilize vessels and ensures efficient nutrient and O2 delivery to perivascular tissues. Also, endothelial cells protect themselves from mitochondrial-derived ROS-mediated damage due to high oxygen levels in the bloodstream. So, it is convincing that the reduced metabolic rate of quiescent endothelial cells is a primary adaptive response.

Endothelial cells respond to changes in environmental conditions, e.g., hypoxia, glucose deprivation, and blood flow-mediated shear stress activates AMPK to promote catabolic pathways in endothelial cells by fatty acid oxidation to produce energy [169, 229, 230]. Besides, AMPK inhibits...
metabolic sensor mammalian targets of rapamycin complex 1 to promote endothelial cell migration and angiogenesis [231, 232]. In addition, another angiogenic regulator, sirtuin 1, also senses endothelial metabolic state [233].

Metaflammation and ectopic fat deposition: effects on cardiovascular disease

Metabolic stress-induced chronic low-grade sterile inflammation due to innate immune response has been termed “metaflammation” [234]. Metaflammation is the critical driver of various chronic diseases, e.g., CVDs, diabetes, nonalcoholic steatohepatitis. In the body, inflammation is tightly controlled by distinct signaling cascades [235]. Pro-inflammatory mediators activate the innate immune system via various pattern recognition receptors [236, 237]. Most studies have focused on damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns to distort the immune system. DAMPs have been found to link with the pathogenesis of chronic metabolic diseases or disorders [238]. But DAMPs are quite varied in structure and origin, and the list of DAMPs is enriching rapidly. Pattern recognition receptors sense free fatty acids, oxidized LDL, cholesterol crystals, glucose, advanced glycation end products. To delineate the inflammatory stimuli due to metabolic stress from other damage-associated immune responses, Wang et al. have used the fresh term “metabolic-associated molecular patterns” [239]. Molecules derived due to persistent excessive FFAs and glucose in plasma are considered to become metabolic-associated molecular patterns or so-called “DAMPs” for innate immune response mediated metaflammation [240, 241].

Pancreatic beta-cell dysfunction, metabolic syndrome, and insulin resistance are correlated with elevated plasma FFAs [242–244]. Toll-like receptor (TLR)-2 or TLR-4 mediated production of interleukin-1β, tumor necrosis factor-α, macrophage inflammatory protein-1α, chemokine (C–C motif) ligand 2, and chemokine (C–C motif) ligand 4 are triggered by upregulated plasma saturated fatty acids [245–250].

Also, oxLDL induces pattern recognition receptors mediated chronic inflammation, which leads to various metabolic diseases or disorders, e.g., atherosclerosis, heart disease, hypertension, obesity [251–254]. 80% oxLDL is taken up by transmembrane scavenger receptors (macrophage scavenger receptor 1, CD36, and lectin-type ox LDL receptor 1) to activate different intracellular signaling pathways, e.g., NF-κB and MAPK [255–257]. Figure 4 shows the metabolic-associated molecular patterns that induce metaflammation. Even oxLDL can form immune complexes with antibodies to activate NLPR3 inflammasome, extracellular signal-regulated kinase 1/2, phospholipase C gamma, c-Jun N-terminal kinase, paxillin, spleen tyrosine kinase, and cell division control protein 42 homolog signaling by Fc gamma receptor, CD36, and/or TLR-4 [258, 259]. Like oxLDL, oxidized phospholipids in platelet induce CD36/TLR-2/TLR-6 complex-mediated MyD88 signaling in the progression of atherothrombosis [260].

Inflammation provokes lipolysis in adipocytes and increases serum FFAs [261, 262]. Similar to adipose tissue, inflammation negatively regulates lipid deposition in skeletal muscle [263]. However, TNFα doesn’t affect fatty acid oxidation but upregulates fatty acid incorporation with diacylglycerol [264–266]. Figure 5 summarises the effects of metaflammation in different organs.

As the prime metabolic organ, de novo lipogenesis (DNL), an influx of FFAs from adipose tissue due to lipolysis, fatty acid oxidation, and VLDL secretion maintain hepatic lipid homeostasis [267]. In addition, inflammation is associated with overexpression of FAT/CD36 and FABPs in the liver [268–270]. Systemic inflammation also increases hepatic de novo lipid synthesis by upregulation of several genes such as sterol regulatory element-binding protein 1c (SREBP-1c), FAS, ACC, and SCD-1, which can be ameliorated by sirtuin1 [271, 272]. More research is required to understand the mechanism of inflammation and its effects on non-adipose tissues.

Conclusions

The endothelium transcends key regulators to the function of every organ system. Endothelium dysfunction can lead to many diseases. Elevated levels of FFAs due to the result of metabolic defects contribute to endothelium dysfunction and subsequently lead to many diseases such as CVD. Dysfunction endothelium develops decreased NO production, increased cytokine production, impaired vasodilation, hyperactivity of platelets, and increased oxidative stress and inflammation. Consuming foods rich in n-3 fatty acids can lower plasma FFAs and other lipids with associated inflammatory cytokines, oxidative stress and may protect the endothelium. However, it would require a better understanding of FFAs and their transport and actions in endothelium and identify some better possible targets that could be used to develop better therapeutic approaches to intervene in the early events endothelium dysfunction.
Fig. 4 Metabolic-associated molecular patterns induce metaflammation. High glucose/fat causes an overload of nutrient metabolites, e.g., glucose, advanced glycation end products, free fatty acids, oxidized LDL, and cholesterol crystal. MAPK and canonical NF-κB pathway-mediated transcription of proinflammatory genes are driven by free fatty acids and/or oxidized LDL-induced TLRs. Transcription factors AP-1 and NF-κB are responsible for inciting the proinflammatory genes. Besides, scavenger receptors take oxidized LDL to form foam cells. Cholesterol crystals can damage the lysosome, which leads to ROS production, K⁺ efflux, and cathepsin leakage. These stimulatory factors activate the NLRP3 inflammasome and result in maturation and secretion of IL-1β and IL-18, thereby instigating metaflammation.
**Acknowledgements**  This work is supported in part by grants from Throne Holst Foundation and the Faculty of Medicine, University Oslo, Norway.

**Authors' contributions**  Both the authors, RM and AKDR, conceived and wrote the review and the figures.

**Funding**  Open access funding provided by University of Oslo (incl Oslo University Hospital). Not Applicable.

**Declarations**

**Conflict of interest**  The authors declare no conflicts of interest.

**Open Access**  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Chlopicki S (2015) Perspectives in pharmacology of endothelium: from bench to bedside. Pharmacol Rep 67:vi–ix. https://doi.org/10.1016/j.pharep.2015.08.005
2. Aird WC (2003) Endothelial cell heterogeneity. Crit Care Med 31:S221–S230. https://doi.org/10.1097/01.CCM.0000057847.32590.C1
3. Lai WK, Kan MY (2015) Homocysteine-induced endothelial dysfunction. Ann Nutr Metab 67:1–12. https://doi.org/10.1159/000437098
4. Luscher TF, Barton M (1997) Biology of the endothelium. Clin Cardiol 20:1–3-II–10
5. Jaffe EA (1987) Cell biology of endothelial cells. Hum Pathol 18:234–239. https://doi.org/10.1016/0046-8177(87)80005-9

---

**Fig. 5**  Effect of metaflammation on different organs. Metaflammation-induced cytokines to increase lipid deposition in the liver, heart, kidney, and pancreas, while lipolysis and fatty acid production are evident in adipose tissue. Similarly, triglyceride content reduces in skeletal muscle following chronic low-grade inflammation.
6. De Caterina R (2000) Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care 3:453–467. https://doi.org/10.1097/00075197-200011000-00007

7. Feletou M, Vanhoutte PM (2006) Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 291:H985–1002. https://doi.org/10.1152/ajpheart.00292.2006

8. Moncada S, Higgs EA (2006) Nitric oxide and the vascular endothelium. Handb Exp Pharmacol. https://doi.org/10.1007/3-540-32967-6_7

9. Munro JM, Cotran RS (1988) The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 58:249–261

10. Jude S, Roger S, Martel E, Besson P, Richard S, Bougnoux PM, Champeaux P, Le Guennec JY (2006) Dietary long-chain omega-3 fatty acids of marine origin: a comparison of their protective effects on coronary heart disease and breast cancers. Prog Biophys Mol Biol 90:299–325. https://doi.org/10.1016/j.pbiomolbio.2005.05.006

11. Egert S, Stehle P (2011) Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care 14:121–131. https://doi.org/10.1097/MCO.0b013e3283439622

12. Hung AM, Booker C, Ellis CD, Siew ED, Graves AJ, Shintani A, Abumrad NN, Himmelfarb J, Ijizler TA (2015) Omega-3 fatty acids inhibit the up-regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrol Dial Transplant 30:266–274. https://doi.org/10.1093/ndt/gnu283

13. Goldberg JI, Bornfeldt KE (2013) Lipids and the endothelium: bidirectional interactions. Curr Atheroscler Rep 15:365. https://doi.org/10.1186/1388-0133-0365-1

14. Ginsberg HN (1991) Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care 14:839–855. https://doi.org/10.2337/diacare.14.9.839

15. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig GL, Van Pelt RE, Wang H, Eckel RH (2008) The triglycerides and cardiovascular disease: bidirectional interactions. Curr Hypertens Rep 3:107–116. https://doi.org/10.1007/s11906-001-0021-y

16. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg NH, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology T, Prevention Committee of the Council on Nutrition PA, Metabolism, Council on Arteriosclerosis T, Vascular B, Council on Cardiovascular N and Council on the Kidney in Cardiovascular D (2011) Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123:2292–333. https://doi.org/10.1161/CIR.0b013e3182160726

17. Egan BM, Greene EL, Goodfriend TL (2001) Nonesterified fatty acids in blood pressure control and cardiovascular complications. Curr Hypertens Rep 3:107–116. https://doi.org/10.1007/s11906-001-0021-y

18. Boden G (2008) Obesity and free fatty acids. Endocrinol Metab Clin N Am 37:635–646, vii–ix. https://doi.org/10.1016/j.ecl.2008.06.007

19. Iantorno M, Campia U, Di Daniele N, Nistico S, Forleo GB, Cardillo C, Tesauro M (2014) Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents 28:169–176

20. Virdis A (2016) Endothelial dysfunction in obesity: role of inflammation. High Blood Press Cardiovasc Prev 23:83–85. https://doi.org/10.1007/s40292-016-0133-8

21. Durrant JR, Seals DR, Connell ML, Russell MJ, Lawson BR, Folian BJ, Donato AJ, Lesniewski LA (2009) Voluntary wheel running restores endothelial function in conduit arteries of old mice: direct evidence for reduced oxidative stress, increased superoxide dismutase activity and down-regulation of NADPH oxidase. J Physiol 587:3271–3285. https://doi.org/10.1113/jphysiol.2009.169771

22. Hadi HA, Carr CS, Al Suwaidi J (2005) Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 1:183–198

23. Guajardo I, Ayer A, Johnson AD, Ganz P, Mills C, Donovan C, Scherer R, Shah SJ, Peralta CA, Dubin RF (2018) Sex differences in vascular dysfunction and cardiovascular outcomes: the cardiac, endothelial function, and arterial stiffness in ESRD (CERES) study. Hemodial Int 22:93–102. https://doi.org/10.1111/hdi.12544

24. Sena CM, Pereira AM, Seica R (2013) Endothelial dysfunction—a major mediator of diabetic vascular disease. Biochim Biophys Acta 1832:2216–2221. https://doi.org/10.1016/j.bbadis.2013.08.006

25. Kuo A, Lee MY, Sessa WC (2017) Lipid droplet biogenesis and function in the endothelium. Circ Res 120:1289–1297. https://doi.org/10.1161/CIRCRESAHA.116.310498

26. Wei X, Schneider JG, Shenouda SM, Lee A, Towler DA, Chakravarty MV, Vita JA, Semenkovich CF (2011) De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation. J Biol Chem 286:2933–2945. https://doi.org/10.1074/jbc.M110.193037

27. Hagberg CE, Falkvall A, Wang X, Larson E, Huuskio J, Nilsson I, van Meeteren LA, Samen E, Lu, VanWildemeersch M, Klar J, Genove G, Pietras K, Stone-Elander S, Claesson-Welsh L, Yla-Herttuala S, Lindahl P, Eriksson U (2010) Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464:917–921. https://doi.org/10.1038/nature08945

28. Schoors S, Brunning U, Missiaen R, Queiroz KC, Borgers G, Elia I, Zecchin A, Cantelmo AR, Christen S, Goveia J, Heggemort W, Godde L, Vinckier S, Van Veldenpp H, Eelen G, Schoonjans L, Gerhardt H, Dewerchin M, Baes M, De Bock K, Ghysenbrique U, Lunt SY, Fenndt SM, Carmeliet P (2015) Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520:192–197. https://doi.org/10.1038/nature14362

29. Patella F, Schug ZT, Persi E, Neilson LJ, Erami Z, Avanzato D, Miano F, Hernandez-Fernaud JR, Mackay G, Zheng L, Reid S, Frezza C, Giraudo E, Fiorio Pla A, Anderson K, Ruppin E, Gottlieb E, Zannivan S (2015) Proteomics-based metabolic modeling reveals that fatty acid oxidation (FAO) controls endothelial cell (EC) permeability. Mol Cell Proteomics 14:621–634. https://doi.org/10.1074/mcp.M114.045575

30. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD (1997) Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100:1230–1239. https://doi.org/10.1172/JCI19636

31. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD (2000) Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 49:1231–1238. https://doi.org/10.2337/diabetes.49.7.1231

32. Pircher A, Treps L, Bodrug N, Carmeliet P (2016) Endothelial cell metabolism: a novel player in atherosclerosis? Basic principles and therapeutic opportunities. Atherosclerosis 253:247–257. https://doi.org/10.1016/j.atherosclerosis.2016.08.011

33. Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109:II27–II32. https://doi.org/10.1161/01.CIR.0000131515.03336.18

34. Kratz M, Cullen P, Kannenberg F, Kassner A, Fobker M, Abaja PM, Assmann G, Wahrburg U (2002) Effects of dietary fatty acids on the composition and oxidizability of low-density lipoprotein. Eur J Clin Nutr 56:72–81. https://doi.org/10.1038/sj.ejcn.1601288

35. Yu YR, Li HL, Zhang XX (2008) Effects of free fatty acids on nitric oxide synthase activity and mRNA expression in
endothelial cell of SD rat aorta. Sichuan Da Xue Xue Bao Yi Xue Ban 39:193–196
36. Wang XL, Zhang L, Youker K, Zhang MX, Wang J, LeMaire SA, Coselli JS, Shen YH (2006) Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes 55:2301–2310. https://doi.org/10.2373/diabetes.05-1574
37. Garcia-Prieto CF, Hernandez-Nuno F, Rio DD, Ruiz-Hurtado G, Aranguez I, Ruiz-Gayo M, Somoza B, Fernandez-Alfonso MS (2015) High-fat diet induces endothelial dysfunction through a down-regulation of the endothelial AMPK-P38-Akt-eNOS pathway. Mol Nutr Food Res 59:520–532. https://doi.org/10.1002/mnfr.201400539
38. Zhang WY, Schwartz E, Wang Y, Attrep J, Li Z, Reaven P (2006) Elevated concentrations of nonesterified fatty acids increase monocyte expression of CD11b and adhesion to endothelial cells. Arterioscler Thromb Vasc Biol 26:514–519. https://doi.org/10.1161/01.ATV.0000200226.53994.09
39. Esenabhalu VE, Schaeffer G, Graier WF (2003) Free fatty acid overload attenuates Ca2+ signaling and NO production in endothelial cells. Antioxid Redox Signal 5:147–153. https://doi.org/10.1089/105208603764816050
40. Mathew M, Tay E, Cusi K (2010) Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 9:9. https://doi.org/10.1186/1475-2840-9-9
41. Yasu T, Kobayashi M, Mutoh A, Yamakawa K, Momomura S, Urata H, Ueda S (2010) Free fatty acid overload attenuates non-esterified-fatty-acid-induced endothelial and rheological dysfunction. Clin Sci (Lond) 120:247–255. https://doi.org/10.1042/CS20120311
42. Luscher TF (2000) Endothelial dysfunction: the role and impact of the renin-angiotensin system. Heart 84(Suppl 1):120–122. https://doi.org/10.1136/heart.84.suppl_1.120 (discussion i50)
43. Pellieux C, Montessuit C, Papageorgiou I, Lerch R (2009) Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-alpha. Cardiovasc Res 82:341–350. https://doi.org/10.1093/cvr/cvp004
44. Sun J, Luo J, Ruan Y, Xu L, Fang B, Zhang H, Wang M, Chen H (2016) Free fatty acids activate renin-angiotensin system in 3T3-L1 adipocytes through nuclear factor-kappa B pathway. J Diabetes Res 2016:1587594. https://doi.org/10.1155/2016/1587594
45. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ, Wark JD, Weisinger HS, Jois M, Weisinger RS (2008) Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 105:6531–6536. https://doi.org/10.1073/pnas.0802690105
46. Azekoshi Y, Yasi T, Watanabe S, Tagawa T, Abe S, Yamakawa K, Uehara Y, Momomura S, Ueda H, Ueda S (2010) Free fatty acid causes leukocyte activation and resultant endothelial dysfunction through enhanced angiotensin II production in mononuclear and polymorphonuclear cells. Hypertension 56:136–142. https://doi.org/10.1161/Hypertensionaha.110.153056
47. Watanabe S, Tagawa T, Yamakawa K, Shimabukuro M, Ueda S (2005) Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 25:2376–2380. https://doi.org/10.1161/01.ATV.0000187465.55507.85
48. Briggs MA, Petersen KS, Kris-Etherton PM (2017) Saturated fatty acids and cardiovascular disease: replacements for saturated fat to reduce cardiovascular risk. Healthcare (Basel). https://doi.org/10.3390/healthcare5020029
49. Mensink RP, Zock PL, Kester AD, Katan MB (2003) Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 77:1146–1155. https://doi.org/10.1093/ajcn/77.5.1146
50. Houston M (2018) The relationship of saturated fats and coronary heart disease: fact or fiction? A commentary. Ther Adv Cardiovasc Dis 12:33–37. https://doi.org/10.1177/1753944717742549
51. Hunter JE, Zhang J, Kris-Etherton PM (2010) Cardiovascular disease risk of dietary stearic acid compared with trans, saturated, and unsaturated fatty acids: a systematic review. Am J Clin Nutr 91:46–63. https://doi.org/10.3945/ajcn.2009.27661
52. Tholstrup T, Marchmann P, Hermansen J, Holmer G, Sandstrom B (1999) Effect of modified dairy fat on fasting and postprandial haemostatic variables in healthy young men. Br J Nutr 82:105–113
53. Hunter KA, Croesbie LC, Weir A, Miller GJ, Dutta-Roy AK (2000) A residential study comparing the effects of diets rich in stearic acid, oleic acid, and linoleic acid on fasting blood lipids, haemostatic variables and platelets in young healthy men. J Nutr Biochem 11:408–416. https://doi.org/10.1016/s0955-2863(00)00097-8
54. Duttaroy AK (2005) Postprandial activation of haemostatic factors: role of dietary fatty acids. Prostaglandins Leukot Essent Fatty Acids 72:381–391. https://doi.org/10.1016/j.plfa.2005.03.003
55. Chen X, Liu L, Palacios G, Gao J, Zhang N, Li G, Lu J, Song T, Zhang Y, Lv H (2010) Plasma metabolomics reveals biomarkers of the atherosclerosis. J Sep Sci 33:2776–2783. https://doi.org/10.1002/jssc.201000395
56. Sokolova M, Vinge LE, Alfsnes K, Olsen MB, Eide L, Kaasboll OA, Atamradal H, Torp MK, Fosshaug LE, Rashidi A, Lien E, Finsen AV, Sandanger O, Aukrust P, Ramheim T, Yndestad A (2017) Palmitate promotes inflammatory responses and cellular senescence in cardiac fibroblasts. Biochim Biophys Acta Mol Cell Biol Lipids 1862:234–245. https://doi.org/10.1016/j.bbalip.2016.11.003
57. Zhang Y, Xia G, Zhang Y, Liu J, Liu X, Li W, Lv Y, Wei S, Liu J, Quan J (2017) Palmitate induces VSMC apoptosis via toll-like receptor (TLR)/4/ROS/p53 pathway. Atherosclerosis 263:74–81. https://doi.org/10.1016/j.atherosclerosis.2017.06.002
58. Das UN (2004) Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension. Eur J Clin Nutr 58:195–203. https://doi.org/10.1038/sj.ejcn.1601766
59. Storniolo CE, Rosello-Catafau J, Pinto X, Mitjavila MT, Moreno JJ (2014) Polypenol fraction of extra virgin olive oil protects against endothelial dysfunction induced by high glucose and free fatty acids through modulation of nitric oxide and endothelin-1. Redox Biol 2:971–977. https://doi.org/10.1016/j.redox.2014.07.001
60. Stirban A, Nandean S, Gotting C, Tamler R, Pop A, Negrean M, Gawlowski T, Stratmann B, Tschoepe D (2010) Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr 91:808–813. https://doi.org/10.3945/ajcn.2009.28374
61. Sawada T, Tsubata H, Hashimoto N, Takabe M, Miyata T, Aoki K, Yamashita S, Oishi S, Osue T, Yoko K, Tsukishiro Y, Onishi T, Shimane A, Taniguchi Y, Yasaka Y, Ohara T, Kawai H, Yokoyama M (2016) Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial. Cardiovasc Diabetol 15:121. https://doi.org/10.1186/s12933-016-0437-y
91. Glatzel DK, Koebel ML, Pein H, Loser K, Stark A, Keksel N, Werz O, Muller R, Bischoff I, Furst R (2018) Acetyl-CoA carboxylase 1 regulates endothelial cell migration by shifting the phospholipid composition. J Lipid Res 59:298–311. https://doi.org/10.1194/jlr.M080101

92. Mitchell JA, Abinet-Shala B, Kirkby NS, Wright WR, Mackenzie LS, Reed DM, Mohamed N (2014) Role of prostacyclin in pulmonary hypertension. Glob Cardiol Sci Pract 2014:382–393. https://doi.org/10.5339/gcsp.2014.33

93. Makki K, Feguell P, Wolowczuk I (2013) Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm 2013:139239. https://doi.org/10.1155/2013/139239

94. Toborek M, Lee YW, Garrido R, Kaiser S, Hennig B (2002) Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. Am J Clin Nutr 75:119–125. https://doi.org/10.1093/ajcn/75.1.119

95. Kuroda R, Hirata K, Kawashima S, Yokoyama M (2001) Unsaturated free fatty acids inhibit Ca2+ mobilization and NO release in endothelial cells. Kobe J Med Sci 47:211–219

96. Jin RC, Voetsch B, Loscalzo J (2005) Endogenous mechanisms of inhibition of platelet function. Microcirculation 12:247–258. https://doi.org/10.1080/107396805909252493

97. Moncada S (2006) Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B 361:735–759. https://doi.org/10.1098/rstb.2005.1775

98. Fritzgerald GA (1991) Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 68:11B–15B. https://doi.org/10.1016/0002-9149(91)90379-y

99. Sixma JJ, van Zanten GH, Huizinga EG, van der Plas RM, Verkley M, Wu YP, Gros P, de Groot PG (1997) Platelet adhesion to collagen: an update. Thromb Haemost 78:434–438

100. Gerritsen ME (1987) Functional heterogeneity of vascular endothelial cells. Biochem Pharmacol 36:2701–2711. https://doi.org/10.1016/0006-2952(87)90252-8

101. Oliver JJ, Webb DJ, Newby DE (2005) Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 25:2470–2479. https://doi.org/10.1161/1074248408322470

102. Byberg L, Smedman A, Vessby B, Lithell H (2001) Plasminogen activator inhibitor-1 and relations to fatty acid composition in the diet and in serum cholesterol esters. Arterioscler Thromb Vasc Biol 21:2086–2092. https://doi.org/10.1161/hq1201.100224

103. Hunter KA, Crosbie LC, Horgan GW, Miller GI, Dutta-Roy AK (2001) Effect of diets rich in oleic acid, stearic acid and linoleic acid on postprandial haemostatic factors in young healthy men. Br J Nutr 86:207–215

104. Hunter KA, Crosbie L, Weir A, Miller GI, Dutta-Roy AK (1997) The effects of physiological meals containing structured triglycerides with different fatty acid compositions on postprandial haemostasis. Atherosclerosis 134:191–191. https://doi.org/10.1016/S0021-9150(97)89899-2

105. Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A (2016) Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta 1858:3131–3140. https://doi.org/10.1016/j.bbamem.2016.10.002

106. Zhang W, Fu F, Tie R, Liang X, Tian F, Xing W, Li J, Li J, Xing J, Sun X, Zhang H (2013) Alpha-linolenic acid intake prevents endothelial dysfunction in high-fat diet-fed streptozotocin rats and underlying mechanisms. Vasa 42:421–428. https://doi.org/10.1024/0301-1526/a000311

107. Gortan Cappellari G, Losurdo P, Mazzuco S, Panizon E, Jevnicar M, Macaluso L, Fabris B, Barazzoni R, Biolo G, Carretta R, Zanetti M (2013) Treatment with n-3 polysaturated fatty acids reverses endothelial dysfunction and oxidative stress in experimental menopause. J Nutr Biochem 24:371–379. https://doi.org/10.1016/j.jnutbio.2012.07.012

108. Lopez D, Orta X, Casos K, Saiz MP, Puig-Parellada P, Farriol M, Mitjavila MT (2004) Upregulation of endothelial nitric oxide synthase in rat aorta after ingestion of fish oil-rich diet. Am J Physiol Heart Circ Physiol 287:H567–H572. https://doi.org/10.1152/ajpheart.01145.2003

109. Jung SB, Kwon SK, Kwon M, Nagar H, Jeon BH, Irani K, Yoon SH, Kim CS (2013) Docosahexaenoic acid improves vascular function via up-regulation of SIRT1 expression in endothelial cells. Biochem Biophys Res Commun 437:114–119. https://doi.org/10.1016/j.bbrc.2013.06.049

110. Siebels CL, Stice JP, Hart CM, Mbai FN, Knowlton AA (2008) Effects of dietary docosahexaenoic acid (DHA) on eNOS in human coronary artery endothelial cells. J Cardiovasc Pharmacol Ther 13:261–268. https://doi.org/10.1177/1074248408322470

111. Omura M, Kobayashi S, Mizukami Y, Mogami K, Todoroki-Ikedu N, Miyake T, Matsuzaki M (2001) Eicosapentaenoic acid (EPA) induces Ca(2+)-independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation. FEBS Lett 487:361–366. https://doi.org/10.1016/S0014-5793(00)03251-6

112. Zanetti M, Grillo A, Losurdo P, Panizon E, Mearelli F, Cattin L, Barazzoni R, Carretta R (2015) Omega-3 polysaturated fatty acids: structural and functional effects on the vascular wall. Biomed Res Int 2015:791978. https://doi.org/10.1155/2015/791978

113. Barden AE, Burke V, Mas E, Belin LJ, Puddey IB, Watts GF, Irish AB, Mori TA (2015) n-3 Fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease. J Hypertens 33:1947–1953. https://doi.org/10.1097/HJH.0000000000000621

114. He K, Liu K, Dagivus ML, Jenny NS, Mayer-Davis E, Jiang R, Steffen L, Siscovich D, Tsai M, Herrington D (2009) Associations of dietary long-chain n-3 polysaturated fatty acids and fish with biomarkers of inflammation and endothelial activation (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol 103:1238–1243. https://doi.org/10.1016/j.amjcard.2009.01.016

115. Poudyal H, Panchal SK, Diwan V, Brown L (2011) Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Prog Lipid Res 50:372–387. https://doi.org/10.1016/j.plipres.2011.06.003

116. Bloomer RJ, Larson DE, Fisher-Wellman KH, Galpin AJ, Schilling BK (2009) Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, crossover study. Lipids Health Dis 8:36. https://doi.org/10.1186/1476-511X-8-36

117. Walker CG, West AL, Browning LM, Madden J, Gambell JM, Jebb SA, Calder PC (2015) The pattern of fatty acids displaced by EPA and DHA following 12 months supplementation varies between blood cell and plasma fractions. Nutrients 7:6281–6293. https://doi.org/10.3390/nu7081978

118. Lagarde M, Calzada C, Guichardant M, Vericel E (2016) In vitro and in vivo bimodal effects of docosahexaenoic acid supplements on redox status and platelet function. Prostaglandins Leukot Essent Fatty Acids 108:1–4. https://doi.org/10.1016/j.prolefa.2016.03.008

119. Phang M, Lincz LF, Garg ML (2013) Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women. J Nutr 143:457–463. https://doi.org/10.3945/jn.112.171249

120. Liu M, Bousssett T, Makni-Maalé K, Fay M, Driss F, El-Benna J, Lagarde M, Guichardant M (2014) Protectin DX, a double
lipoxigenase product of DHA, inhibits both ROS production in human neutrophils and cyclooxygenase activities. Lipids 49:49–57. https://doi.org/10.1007/s11745-013-3863-6

121. Lagarde M, Calzada C, Guichardant M, Vericel E (2013) Dose-effect and metabolism of docosahexaenoic acid: pathophysiological relevance in blood platelets. Prostaglandins Leukot Essent Fatty Acids 88:49–52. https://doi.org/10.1016/j.plefa.2012.04.001

122. Leray C, Wiesel ML, Freund M, Cazenave JP, Gachet C (2001) Arachidonic and eicosapentaenoic acids increase plasma triglycerides in hyperlipidemic: a study of hepatic gene expression in APOE2 knock-in mice. Arterioscler Thromb Vasc Biol 21:459–465. https://doi.org/10.1161/01.ATV.21.3.459

123. Vanschoonebeek K, Wouters K, van der Meijden PE, van Gorp PJ, Feijge MA, Herfs M, Schurgers LJ, Holfer MH, de Maat MP, Heemskerk JW (2008) Anticoagulant effect of dietary fish oil in hyperlipidemia. Lipids Health Dis 10:18. https://doi.org/10.1186/1476-511X-10-18

124. Bang HO, Dyerberg J (1972) Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand 192:85–94. https://doi.org/10.1165/ATVBAHA.107.156992

125. Lagarde M, Calzada C, Guichardant M, Vericel E (2013) Dose-effect and metabolism of docosahexaenoic acid: pathophysiological relevance in blood platelets. Prostaglandins Leukot Essent Fatty Acids 88:49–52. https://doi.org/10.1016/j.plefa.2012.04.001

126. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Dyerberg J, Bang HO, Hjorne N (1977) Plasma cholesterol concentration in Greenlandic west coast Eskimos. Acta Med Scand 192:85–94. https://doi.org/10.1165/ATVBAHA.107.156992

127. Harris WS, Bulchandani D (2006) Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17:387–393. https://doi.org/10.1097/01.oli.0000236363.63840.16

128. Landa V, Zidek V, Meljnek P, Simakova M, Silhavy J, Trnovska M, Zidek V, Meljnek P, Simakova M, Silhavy J, Trnovska M, Landa V, Zidek V, Meljnek P, Simakova M, Silhavy J, Trnovska M (2006) Plasma fatty acid composition is associated with the hepatic apolipoprotein B degradation and VLDL production. J Clin Lipid 43:177–186.

129. Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Walczak R, Tontonoz P (2002) PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. Biochim Biophys Acta 1581/01. atv. 21.3.459

130. Heemskerk JW (2008) Anticoagulant effect of dietary fish oil in hyperlipidemia: a study of hepatic gene expression in APOE2 knock-in mice. Arterioscler Thromb Vasc Biol 28:2023–2029. https://doi.org/10.1161/ATVBAHA.107.156992

131. Lagarde M, Calzada C, Guichardant M, Vericel E (2013) Dose-effect and metabolism of docosahexaenoic acid: pathophysiological relevance in blood platelets. Prostaglandins Leukot Essent Fatty Acids 88:49–52. https://doi.org/10.1016/j.plefa.2012.04.001

132. Fisher EA, Pan M, Chen X, Wu X, Wang H, Jamil H, Sparks JD, Klein-Platat C, Drai J, Oujaa M, Schlienger JL, Simon C, Eiselein L, Wilson DW, Lame MW, Rutledge JC (2007) Plasma fatty acid composition is associated with the hepatic apolipoprotein B degradation and VLDL production. J Clin Lipid 43:177–186.

133. Mason RP, Sherratt SC, Jacob RF (2016) Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triacylceride-lowering agents. J Cardiovasc Pharmacol 68:33–40. https://doi.org/10.1097/JFC.0000000000000379

134. Mason RP, Sherratt SC, Jacob RF (2016) Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triacylceride-lowering agents. J Cardiovasc Pharmacol 68:33–40. https://doi.org/10.1097/JFC.0000000000000379

135. McNees GT (2005) Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl 23:S3-8. https://doi.org/10.1097/01.jhyp.0000165622.34192.f2

136. Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Walczak R, Tontonoz P (2002) PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. Biochim Biophys Acta 1581/01. atv. 21.3.459
150. Theodorou K, Boon RA (2018) Endothelial cell metabolism in atherosclerosis. Front Cell Dev Biol 6:82. https://doi.org/10.3389/fcell.2018.00082

151. Pi X, Xie L, Patterson C (2018) Emerging roles of vascular endothelium in metabolic homeostasis. Circ Res 123:477–494. https://doi.org/10.1161/CIRCRESAHA.118.313237

152. Duttaroy AK (2009) Transport of fatty acids across the human placenta: a review. Prog Lipid Res 48:52–61. https://doi.org/10.1016/j.plipres.2008.11.001

153. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arliott M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9:311–326. https://doi.org/10.1016/j.cmet.2009.02.002

154. Iso T, Maeda K, Hanaoka H, Suga T, Goto K, Syamsunarno MR, Duttaroy AK (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9:311–326. https://doi.org/10.1016/j.cmet.2009.02.002

155. Sawane M, Kajiya K, Kidoya H, Takagi M, Muramatsu F, Coburn CT, Knapp FF Jr, Febbraio M, Beets AL, Silverstein RL, Abumrad NA, Sano M, Suematsu M, Endo K, Hotamisligil GS, Kurabayashi M (2013) Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle. Arterioscler Thromb Vasc Biol 33:2549–2557. https://doi.org/10.1161/ATVBAHA.113.301588

156. Sawane M, Kajiya K, Kidoya H, Takagi M, Muramatsu F, Takakura N (2013) Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes 62:1970–1980. https://doi.org/10.2337/db12-0604

157. Hwangbo C, Wu J, Papangel i I, Adachi T, Sharma B, Park S, Zhao L, Ju H, Go GW, Cui G, Inayathullah M, Job JK, Rajadas J, Kwei SL, Li MO, Morrison AR, Tandon NN, Luiken JJ, Glatz JF, Luiken JJ, Bock J, Shai D, Yang K, Su X, Gross RW, Nakamura R, Abumrad NA (2015) CD36 enhances fatty acid uptake by increasing the rate of intracellular esterification but not transport across the plasma membrane. Biochemistry 52:7254–7261. https://doi.org/10.1021/bi400914c

158. Hardie DG, Schaffer BE, Brunet A (2016) AMPK: an energy-sensing pathway with multiple inputs and outputs. Trends Cell Biol 26:190–201. https://doi.org/10.1016/j.tcb.2015.10.013

159. Xu S, Jay A, Brunaldi K, Huang N, Hamilton JA (2013) CD36 enhances fatty acid uptake by increasing the rate of intracellular esterification but not transport across the plasma membrane. Biochemistry 52:7254–7261. https://doi.org/10.1021/bi400914c

160. Samovski D, Sun J, Pietka T, Gross RW, Eckel RH, Su X, Stahl PD, Abumrad NA (2015) Regulation of AMPK activation by CD36 links fatty acid uptake to beta-oxidation. Diabetes 64:353–359. https://doi.org/10.2337/db14-0582

161. Ruderman NB, Carling D, Prentki M, Cacicedo JM (2013) AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 123:2764–2772. https://doi.org/10.1172/JCI67727

162. Nahle Z, Hsieh M, Pietka T, Coburn CT, Grimaldi FA, Zhang MQ, Das D, Abumrad NA (2008) CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPAR delta/beta-mediated adaptation to metabolic stress. J Biol Chem 283:14317–14326. https://doi.org/10.1074/jbc.M706478200

163. Pietka TA, Sulkin MS, Kuda O, Wang W, Zhou D, Yamada KA, Yang K, Su X, Gross RW, Berthoume JM, Efimov IR, Abumrad NA (2012) CD36 protein influences myocardial Ca2+ homeostasis and phospholipid metabolism: conduction anomalies in CD36-deficient mice during fasting. J Biol Chem 287:38901–38912. https://doi.org/10.1074/jbc.M112.413609

164. Kuda O, Jenkins CM, Skinner JR, Moon SH, Su X, Gross RW, Abumrad NA (2011) CD36 protein is involved in store-operated calcium flux, phospholipase A2 activation, and production of prostaglandin E2. J Biol Chem 286:17785–17795. https://doi.org/10.1074/jbc.M111.232975

165. Pratikia M, Lewis RS (2015) Store-operated calcium channels. Physiol Rev 95:1383–1436. https://doi.org/10.1152/physrev.00020.2014

166. Neckar J, Sihavy J, Zidek V, Vanda L, Mlejnek P, Simakova M, Seidman JG, Seidman C, Kazdova L, Klevstig M, Novak F, Vecka M, Papousek F, Houstruk J, Drahota Z, Kurzh T, Kolar F, Pervanec M (2012) CD36 overexpression predisposes to arrhythmias but reduces infarct size in spontaneously hypertensive rats: gene expression profile analysis. Physiol Genomics 44:173–182. https://doi.org/10.1152/physiogenomics.00083.2011
177. Jabs M, Rose AJ, Lehmann LH, Taylor J, Moll I, Sijmonsma TP, Herberich SE, Sauer SW, Poschet G, Federico G, Mogler C, Weis EM, Augustin HG, Yan M, Grett N, Schmid RM, Adams RH, Grone HJ, Hell R, Okun JG, Backs J, Nawroth PP, Herzig S, Fischer A (2018) Inhibition of endothelial notch signaling impairs fatty acid transport and leads to metabolic and vascular remodeling of the adult heart. Circulation 137:2592–2608. https://doi.org/10.1161/CIRCULATIONAHA.117.029753

178. Hasan SS, Jabs M, Taylor J, Wiedmann L, Leibing T, Nordstrom V, Federico G, Roma LP, Carlemin C, Wolff G, Ekim-Ustunel B, Brune M, Moll I, Tetzlaff F, Grone HJ, Fleming T, Geraud C, Herzig S, Nawroth PP, Fischer A (2020) Endothelial Notch signaling controlling insulin transport in muscle. EMBO Mol Med 12:e9271. https://doi.org/10.15252/emmm.201809271

179. Bae H, Hong KY, Lee CK, Jang C, Lee SJ, Choe K, Offermanns S, He Y, Lee HJ, Koh GY (2020) Angiopoietin-2-integrin alphabeta1 signaling enhances vascular fatty acid transport and prevents ectopic lipid-induced insulin resistance. Nat Commun 11:2980. https://doi.org/10.1038/s41467-020-16795-4

180. Molino Y, David M, Varini K, Jabes F, Brune M, Tetzlaff F, Lecorche P, Temsamani J, Jacquot G, Khrestchatisky M (2017) Use of LDL receptor-targeting peptide vectors for in vitro and in vivo cargo transport across the blood-brain barrier. FASEB J 31:1807–1827. https://doi.org/10.1096/fj.201606827R

181. Mao H, Lockyer P, Li L, Ballantyne CM, Patterson C, Xie L, Pi X (2017) Endothelial LRPI regulates metabolic responses by acting as a co-activator of PPARgamma. Nat Commun 8:14960. https://doi.org/10.1038/ncomms14960

182. Davies BS, Goulbourne CN, Barnes RH 2nd, Turlo KA, Gin P, Vaughan S, Vaux DJ, Bensadoun A, Beigneux AP, Fong LG, Young SG (2012) Assessing mechanisms of GPIHBP1 and lipoprotein lipase movement across endothelial cells. J Lipid Res 53:2690–2697. https://doi.org/10.1194/jlr.M031559

183. Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, Khovidhunkit W, Dufour R, Garg A, McMahon MA, Pullinger CR, Sandoval NP, Hu X, Allan CM, Larsson M, Machida T, Murakami M, Reue K, Tontonoz P, Goldberg IJ, Moulin P, Charriere S, Fong LG, Nakajima K, Young SG (2017) Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia. N Engl J Med 376:1647–1658. https://doi.org/10.1056/NEJMoa1611930

184. Furuhashi M, Fuchu R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS (2008) Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 118:2640–2650. https://doi.org/10.1172/JCI34750

185. Dutta-Roy AK, Gopalswamy N, Trulzsch DV, Arikan MC, Ghelfi E, Karaaslan C, Orend G, Yu CW, Silva S, He Y, Lee HJ, Koh GY (2020) Angiopoietin-2-integrin alpha1611930 binds to Z protein of rat liver. Eur J Biochem 162:615–620. https://doi.org/10.1111/j.1432-1033.1987.tb10683.x

186. Dutta-Roy AK (2000) Cellular uptake of long-chain fatty acids: role of membrane-associated fatty-acid-binding/transport proteins. Cell Mol Life Sci 57:1360–1372. https://doi.org/10.1007/pl00000621

187. Cataltepe O, Arikan MC, Ghelfi E, Karaaslan C, Ossurekci Y, Dresser K, Li Y, Smith TW, Cataltepe S (2012) Fatty acid binding protein 4 is expressed in distinct endothelial and non-endothelial cell populations in glioblastoma. Neuropathol Appl Neurobiol 38:400–410. https://doi.org/10.1111/j.1365-2990.2011.01237.x

188. Elmasri H, Ghelfi E, Yu CW, Traphagen S, Cermans M, Cao H, Shi GP, Plutzky J, Sahin M, Hotamisligil GS, Cataltepe S (2012) Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis 15:457–468. https://doi.org/10.1007/s10456-012-9274-0

189. Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA, Kozakewich H, Bischoff J, Cataltepe S (2009) Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 23:3865–3873. https://doi.org/10.1096/fj.09-134882

190. Ghelfi E, Yu CW, Elmasri H, Terwel M, Lee CG, Bhandari V, Comhair SA, Erzurum SC, Hotamisligil GS, Elias JA, Cataltepe S (2013) Fatty acid binding protein 4 regulates VEGF-induced airway angiogenesis and inflammation in a transgenic mouse model: implications for asthma. Am J Pathol 182:1425–1433. https://doi.org/10.1016/j.ajpath.2012.12.009

191. Masouyé I, Hagens V, Van Kuppevelt TH, Madsen P, Saurat JH, Veerkamp JH, Pepper MS, Siegenthaler G (1997) Endothelial cells of the human microvasculature express epidermal fatty acid-binding protein. Circ Res 81:297–303

192. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Stambousian Y, Kahn BB, Parker RA, Hotamisligil GS (2005) Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 1:107–119. https://doi.org/10.1016/j.cmet.2004.12.008

193. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS (2004) Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival inapolipoprotein E-deficient mice. Circulation 110:1492–1498. https://doi.org/10.1161/01.CIR.0000014735.13202.B6

194. Antohe F, Popov D, Radulescu S, Simionescu N, Borcherz T, Spener F, Simionescu M (1998) Heart microvessels and aortic endothelial cells express the 15 kDa heart-type fatty acid-binding proteins. Eur J Cell Biol 76:102–110. https://doi.org/10.1016/S0171-9335(98)80022-8

195. Yu CW, Liang X, Lipsky S, Karaaslan C, Kozakewich H, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Thorogood Y, Kahn BB, Parker RA, Hotamisligil GS (2016) Dual role of fatty acid-binding protein 5 on endothelial cell fate: a potential link between lipid metabolism and angiogenic responses. Angiogenesis 19:95–106. https://doi.org/10.1007/s10456-015-9491-4

196. Potente M, Gerhardt H, Carmeliet P (2011) Basic and therapeutic aspects of angiogenesis. Cell 146:873–887. https://doi.org/10.1016/j.cell.2011.08.039

197. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464–478. https://doi.org/10.1038/nrm2183

198. Gerhardt H, Goldberg M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsoltz C (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163–1177. https://doi.org/10.1083/jcb.200302047

199. Geudens I, Gerhardt H (2011) Coordinating cell behaviour during blood vessel formation. Development 138:4569–4583. https://doi.org/10.1242/dev.062323

200. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Opalakr S, de Oliveira RL, Loges S, Schmidt T, Jonck B, Tian Y, Lanahan AA, Pollard P, de Almodovar CR, De Smet F, Vincik S, Aragones J, Debackere K, Luttun A, Wynn S, Jordan B, Pisacane A, Galeze B, Lampugnani MG, Dejana E, Simonis M, Ratcliffe P, Maxwell P, Carmeliet P (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839–851. https://doi.org/10.1016/j.cell.2009.01.020
202. Van de Vondele S, Dewerchin M, Carmeliet P (2015) Angiogenesis revisited: an overlooked role of endothelial cell metabolism in vessel sprouting. Microcirculation 22:509–517. https://doi.org/10.1111/mic.12229
203. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033. https://doi.org/10.1126/ science.1160809
204. Culic O, Grivel ML, Schrader J (1997) Energy turnover of vascular endothelial cells. Am J Physiol 273:C205–C213. https://doi.org/10.1152/ajpcell.1997.273.1.C205
205. De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quezbeur A, Ghesquiere B, Cauwenberghs S, Eelen G, Ping LK, Betz I, Tamberuys B, Brepoels K, Welti J, Geudens I, Segura I, Crays B, Bifari F, Decimo L, Blanco R, Wynn S, Vangindertael J, Rocha S, Collins RT, Munck S, Daelemans D, Imamura H, Devlieger R, Rider M, Van Veldhoven PP, Schuit F, Bartsch R, Hofkens J, Frutiger M, Vandekeere S, Dewerchin M, Carmeliet P (2015) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154:651–663. https://doi.org/10.1016/j.cell.2015.06.037
206. Markowska AJ, Jefferies KC, Panjwani N (2011) Galectin-3 promotes cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem 286:29913–29921. https://doi.org/10.1074/jbc.M111.226423
207. Vandekeere S, Dewerchin M, Carmeliet P (2015) Angiogenesis revisited: an overlooked role of endothelial cell metabolism in vessel sprouting. Cell 154:651–663. https://doi.org/10.1016/j.cell.2015.06.037
208. Ebert BL, Gleadle JM, O’Rourke JF, Bartlett SM, Poulton J, Ratmans D, Imamura H, Devlieger R, Serrenk H, Rocha S, Collins RT, Munck S, Daelemans D, Imamura H, Devlieger R, Rider M, Van Veldhoven PP, Schuit F, Bartsch R, Hofkens J, Frutiger M, Vandekeere S, Dewerchin M, Carmeliet P (2013) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154:651–663. https://doi.org/10.1016/j.cell.2013.06.037
209. Obach M, Navarro-Sabate A, Caro J, Kong X, Duran J, Gomez M, Perales JC, Ventura F, Rosa JL, Bartrons R (2004) 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. J Biol Chem 279:53562–53570. https://doi.org/10.1074/jbc.M201095200
210. Benedito R, Roca C, Sorensen L, Adams S, Gossler A, Fruttiger M, Adams RH (2009) The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137:1124–1135. https://doi.org/10.1016/j.cell.2009.03.025
211. Parra-Bonilla G, Alvarez DF, Al-Mehdi AB, Alexeyev M, Steenson L522. https://doi.org/10.1152/ajplu ng.00274.2009
212. Schug ZT, Frezza C, Galbraith LC, Gottlieb E (2012) The music of lipid gradients orchestrates cellular behaviour. Acta Oncol 51:301–310. https://doi.org/10.3109/0284166X.2011.643823
213. Jones RG, Thompson CB (2009) Tumor suppressors and cell proliferation. Science 324:1029–1033. https://doi.org/10.1126/science.1160809
214. Hahn GL, Polgar PR (1984) Prostaglandin production in peripheral blood lymphocytes: how lipid composition orchestrates cellular behaviour. Biochem Acta 739:93–96. https://doi.org/10.1016/S0005-1281(83)80080-4
215. Vizan P, Sanchez-Tena S, Alcarraz-Vizan G, Soler M, Messegue R, Pujol MD, Lee WN, Cascante M (2009) Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis 30:946–952. https://doi.org/10.1093/carcin/bgp083
216. Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, Newhouse L, Ogrodzinski M, Hecht V, Xu K, Acevedo PN, Hollera DP, Bellinger G, Dayton TL, Christen S, Elia I, Dinh AT, Stephanopoulos G, Manalis SR, Yaffe MB, Andrechek ER, Fedn SM, Vander Heiden MG (2015) Pyruvate kinase isomerase expression alters nucleotide synthesis to impact cell proliferation. Mol Cell 57:95–107. https://doi.org/10.1016/j.molcel.2014.10.027
217. Liu XH, Kirschenbaum A, Yao S, Dosoretz A, Holland JF, Levine AC (2002) Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277:50081–50086. https://doi.org/10.1074/jbc.M201095200
218. Hahn GL, Polgar PR (1984) Prostaglandin production in phenotypically distinct cultured bovine pulmonary artery endothelium. Atherosclerosis 51:143–150. https://doi.org/10.1016/0021-9150(84)90150-3
219. Kuwashima L, Graeber J, Glaser BM (1988) Stimulation of endothelial cell prostacyclin release by retina-derived factors. Invest Ophtalmol Vis Sci 29:1213–1220
220. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM (1998) Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97:99–107. https://doi.org/10.1161/01.cir.97.1.99
221. Wilhelm K, Happel K, Eelen G, Schoors S, Oellerich MF, Lim R, Zimmermann B, Aspalter IM, Franco CA, Boettiger T, Braun T, Fruttiger M, Rajewsky K, Keller C, Brunning JC, Gerhardt H, Carmeliet P, Potente M (2016) FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature 529:216–220. https://doi.org/10.1038/nature16498
222. Hsieh AL, Walton ZE, Altmann BJ, Stine ZE, Dang CV (2015) MYC and metabolism on the path to cancer. Semin Cell Dev Biol Mol 35:114–127. https://doi.org/10.1016/j.secmdb.2015.08.003
223. Kato T, Thompson CB (2009) Tumor suppressor p53 regulates AMP-activated protein kinase in endothelial cells. Circ Res 105:114–127. https://doi.org/10.1161/CIRCRESAHA.109.315901
224. Dagher Z, Ruderman N, Tornheim K, Ido Y (2001) Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. Circ Res 88:1276–1282. https://doi.org/10.1161/01.hh1201.092998
231. Nagata D, Mogi M, Walsh K (2003) AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 278:31000–31006. https://doi.org/10.1074/jbc.M300643200

232. Eleyan A, Comb WC, Sabatini DM (2015) Nutrient-sensing mechanisms and pathways. Nature 517:302–310. https://doi.org/10.1038/nature14190

233. Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, Dequiedt F, Haendeler J, Mioene M, Dejeana E, Ait FZ, Zehrer AM, Dimmeler S (2007) SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 21:2644–2658. https://doi.org/10.1101/gad.435107

234. Antonelli M, Kushner I (2017) It’s time to redefine inflammation. FASEB J 31:1787–1791. https://doi.org/10.1096/fj.201601326R

235. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L (2018) Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9:7204–7218. https://doi.org/10.18632/oncotarget.23208

236. Taniguchi K, Karin M (2018) NF-kappaB, inflammation, immune and cancer: coming of age. Nat Rev Immunol 18:309–324. https://doi.org/10.1038/nri.2017.142

237. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140:805–820. https://doi.org/10.1016/j.cell.2010.01.022

238. Rozenfield R, Devi LA (2010) Receptor heteromerization and assembly. Curr Opin Clin Nutr Metab Care 10:142–148. https://doi.org/10.1016/j.cocnc.2009.02.003

239. Wang Y, Qian Y, Fang Q, Zhong P, Li W, Wang L, Fu W, Zhang X, Zhao L (2018) Metabolic inflamming-cell signaling. Trends Pharmacol Sci 31:124–130. https://doi.org/10.1016/j.tips.2010.01.022

240. Rozenfield R, Devi LA (2010) Receptor heteromerization and assembly. Curr Opin Clin Nutr Metab Care 10:142–148. https://doi.org/10.1016/j.cocnc.2009.02.003

241. Lyons CL, Kennedy EB, Roche HM (2016) Metabolic inflammation-differential modulation by dietary constituents. Nutrients. https://doi.org/10.3390/nu9050247

242. Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F, Yagi N, Ohto U, Kimoto M, Miyake T, Tobe K, Arai H, Kadowaki T, Nagai R (2012) Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab 15:518–533. https://doi.org/10.1016/j.cmet.2012.01.023

243. Delarue J, Magnan C (2007) Free fatty acids and insulin resistance.Curr Opin Clin Nutr Metab Care 10:142–148. https://doi.org/10.1016/j.cocnc.2009.02.003

244. Wang Y, Wang Y, Antony V, Sun H, Liang G (2020) Metabolism-associated molecular patterns (MAMPs). Trends Endocrinol Metab 31:712–724. https://doi.org/10.1016/j.tem.2020.07.001

245. Schaefer L (2014) Complexity of danger: the diverse nature of danger-associated molecular patterns in organisms. Oncotarget 9:7204–7218. https://doi.org/10.18632/oncotarget.23208

246. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140:805–820. https://doi.org/10.1016/j.cell.2010.01.022

247. Rozenfield R, Devi LA (2010) Receptor heteromerization and assembly. Curr Opin Clin Nutr Metab Care 10:142–148. https://doi.org/10.1016/j.cocnc.2009.02.003

248. Wang Y, Qian Y, Fang Q, Zhong P, Li W, Wang L, Fu W, Zhang X, Zuo Z, Deng J, Li Y, Wang X, Zhao L (2018) Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9:7204–7218. https://doi.org/10.18632/oncotarget.23208

249. Kochumon S, Wilson A, Chen H, Shenaodu S, Tuomilehto J, Siddhu S, Ahmad R (2018) Palmitate activates CCL4 expression in human monocytes via TLR4/MyD88 dependent activation of NF-kappaB/MAPK/PI3K signaling systems. Cell Physiol Biochem 46:953–964. https://doi.org/10.1007/s00592-018-10216-5

250. Yang W, Cao M, Xiao X, Wei X, Li X, Chen G, Zhang Z, Shi J, Huang H, Yao X, Liu C (2016) Alternate-day fasting protects the livers of mice against high-fat diet-induced inflammation associated with the suppression of Toll-like receptor 4/nuclear factor kappaB signaling. Nutr Res 36:586–593. https://doi.org/10.1016/j.nutres.2016.02.001

251. Moyer BJ, Rojas IY, Kerley-Hamilton JS, Hazlett HF, Nemani KV, Trask HW, West RJ, Lupien LE, Collins AJ, Ringelberg CS, Gimi B, Kinlaw WB 3rd, Tomlinson CR (2016) Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenic via oxidized-LDL, TLR2/4, TGF-beta, and IDO1. Toxicol Appl Pharmacol 352:1–13. https://doi.org/10.1016/j.taap.2016.03.011

252. Catar RA, Muller G, Heidler J, Schmitz G, Bornstein SR, Morawietz H (2007) Low-density lipoproteins induce the renin-angiotensin system and their receptors in human endothelial cells. Horm Metab Res 39:801–805. https://doi.org/10.1055/s-2007-991158

253. Kita T, Nokone Y, Kadowaki T, Arih Horiuchi H, Moriwaki H, Minami M, Kataoka H, Watauchi Y (2000) Oxidized-LDL and atherosclerosis. Role of LOX-1. Ann Y Acad Sci 902:95–100. https://doi.org/10.1111/j.1749-6632.2000.tb06304.x (discussion 100-2)

254. Koenig W, Karakas M, Zierer A, Herder C, Baemert M, Meisinger C, Thorand B (2011) Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study. Clin Chem 57:1196–1200. https://doi.org/10.1373/clinchem.2011.165134

255. Zani IA, Stephen SL, Mughal NA, Russell D, Homer-Vanniasinkam S, Wheatscroft SB, Ponnambalam S (2015) Scavenger receptor structure and function in health and disease. Cells 4:178–201. https://doi.org/10.3390/cells4020017

256. Vohra RS, Murphy JE, Walker JH, Ponnambalam S, Homer-Vanniasinkam S (2006) Atherosclerosis and the lectin-like oxidized-low-density lipoprotein scavenger receptor. Trends Cardiovasc Med 16:60–64. https://doi.org/10.1016/j.tcm.2005.12.001

257. Chen M, Qiu H, Lin X, Nam D, Ogbaru-Nwobodo L, Archibald H, Joslin A, Sawamura T, Green R (2016) Lectin-like oxidized-low-density lipoprotein receptor (LOX-1) in sickle cell disease vasculopathy. Blood Cells Mol Dis 60:44–48. https://doi.org/10.1016/j.bcmd.2016.06.005

258. Rhoads JP, Lukens JR, Wilhelm AJ, Moore JL, Mendez-Fernandez J, Witztum JL, Miller YI (2013) Polyoxygenated cholesterol ester invasion-differential modulation by dietary constituents. Nutrients. https://doi.org/10.3390/nu5030097

259. Ahmad R, Akhter N, Al-Roub A, Kochumon S, Wilson A, Thomas R, Kumari M, Koshy MS, Tiss A, Hannun YA, Tuomilehto J, Siddhu S, Rosen ED (2018) The synergy between palmitate and TNF-alpha for CCL2 production is dependent on the TRIF/IRF3 pathway: implications for metabolic inflammation. j Immunol 200:3599–3611. https://doi.org/10.4049/jimmunol.1701552

260. Vohra RS, Murphy JE, Walker JH, Ponnambalam S, Homer-Vanniasinkam S (2006) Atherosclerosis and the lectin-like oxidized-low-density lipoprotein scavenger receptor. Trends Cardiovasc Med 16:60–64. https://doi.org/10.1016/j.tcm.2005.12.001

261. Biswas S, Zimmer M, Gao D, Byzova TV, Podrez EA (2017) TLR2 plays a key role in platelet hyperreactivity and accelerated thrombosis associated with hyperlipidemia. Circ Res 124:212–224. https://doi.org/10.1161/CIRCRESAHA.116.3080015
261. Kim JY, Tillison K, Lee JH, Rearick DA, Smas CM (2006) The adipose tissue triglyceride lipase ATGL/PNPLA2 is downregulated by insulin and TNF-alpha in 3T3-L1 adipocytes and is a target for transactivation by PPARgamma. Am J Physiol Endocrinol Metab 291:E115–E127. https://doi.org/10.1152/ajpendo.00317.2005

262. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M (2005) Isoproterenol, TNFalpha, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes. Mol Cell Endocrinol 240:43–49. https://doi.org/10.1016/j.mce.2005.06.002

263. Liu L, Mei M, Yang S, Li Q (2014) Roles of chronic low-grade inflammation in the development of ectopic fat deposition. Mediators Inflamn 2014:418185. https://doi.org/10.1155/2014/418185

264. Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364–3375. https://doi.org/10.1210/me.2005-0490

265. Bruce CR, Dyck DJ (2004) Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 287:E616–E621. https://doi.org/10.1152/ajpendo.00150.2004

266. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnes-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Fevbraio MA (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688–2697. https://doi.org/10.2337/db05-1404

267. Nguyen P, Leray V, Diez M, Serisier S, Le Bloc’h J, Siliart B, Dumon H (2008) Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 92:272–283. https://doi.org/10.1011/j.1439-0396.2007.00752.x

268. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kivimuoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-Jarvinen H (2008) Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 294:G1281–G1287. https://doi.org/10.1152/ajpgi.00074.2008

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.